PRODUCT NAME
REMICADE® (infliximab) 100 mg powder for concentrate for solution for infusion.

DOSAGE FORMS AND STRENGTHS
REMICADE® is available as a powder for concentrate for solution for infusion.

The powder is a freeze-dried white pellet.

Each vial of REMICADE® contains 100 mg of infliximab, a chimeric human-murine IgG1 monoclonal antibody produced in murine hybridoma cells by recombinant DNA technology. Upon reconstitution, each ml contains 10 mg of infliximab.

For excipients, see *List of Excipients*.

CLINICAL INFORMATION
Indications
Rheumatoid Arthritis
REMICADE®, in combination with methotrexate (MTX), is indicated for:
The reduction of signs and symptoms as well as the improvement in physical function in
- patients with active disease when the response to disease-modifying drugs, including methotrexate, has been inadequate.
- patients with severe, active and progressive disease not previously treated with methotrexate or other DMARDs.

In these patient populations, a reduction in the rate of the progression of joint damage, as measured by x-ray, has been demonstrated (see *Pharmacodynamic Properties*).

Crohn's Disease
REMICADE® is indicated for:
- Treatment of moderately to severely, active Crohn's disease, in patients who have not responded despite a full and adequate course of therapy with a corticosteroid and an immunosuppressant; or who are intolerant to or have medical contraindications for such therapies.
- Treatment of fistulising Crohn's disease, in patients who have not responded despite a full and adequate course of therapy with conventional treatment (including antibiotics, drainage and immunosuppressive therapy).

Pediatric Crohn's Disease
REMICADE® is indicated for:
Treatment of severe, active Crohn's disease, in pediatric patients aged 6 to 17 years, who have not responded to conventional therapy including a corticosteroid, an immunomodulator and primary nutrition therapy; or who are intolerant to or have contraindications for such therapies. REMICADE® has been studied only in combination with conventional immunosuppressive therapy.

Ulcerative Colitis
REMICADE® is indicated for:
Treatment of moderately to severely active ulcerative colitis in patients who have had an inadequate response to conventional therapy including corticosteroids and 6-mercaptopurine (6-MP) or azathioprine (AZA), or who are intolerant to or have medical contraindications for such therapies.

Pediatric Ulcerative Colitis
REMICADE® is indicated for:
Reducing signs and symptoms and inducing and maintaining clinical remission in pediatric patients 6 years of age and older with moderately to severely active ulcerative colitis who have had an inadequate response to conventional therapy.

Ankylosing Spondylitis
REMICADE® is indicated for:
Treatment of ankylosing spondylitis, in patients who have severe axial symptoms, elevated serological markers of inflammatory activity and who have responded inadequately to conventional therapy.

Psoriatic Arthritis
REMICADE®, in combination with methotrexate, is indicated for:
Treatment of active and progressive psoriatic arthritis in patients who have responded inadequately to disease-modifying anti-rheumatoid drugs.

Psoriasis
REMICADE® is indicated for:
Treatment of moderate to severe plaque psoriasis in adults who failed to respond to, or who have a contraindication to, or are intolerant to other systemic therapy including cyclosporine, methotrexate or PUVA (see *Pharmacodynamic Properties*)

Dosage and Administration
REMICADE® treatment is to be administered under the supervision and monitoring of specialised physicians experienced in the diagnosis and treatment of rheumatoid arthritis, inflammatory bowel diseases, ankylosing spondylitis, psoriatic arthritis or psoriasis. REMICADE® should be administered intravenously.

During REMICADE® treatment, other concomitant therapies, e.g., corticosteroids and immunosuppressants should be optimised.

Dosage - Adults (≥ 18 years)
REMICADE® is administered by intravenous infusion.

Rheumatoid Arthritis
3 mg/kg given as an intravenous infusion over a 2-hour period followed by additional 3 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.

REMICADE® must be given concomitantly with methotrexate.

Available data suggest that the clinical response is usually achieved within 12 weeks of treatment. Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit within this time period.

Moderately to Severely, Active Crohn's Disease
5 mg/kg given as an intravenous infusion over a 2-hour period. Available data do not support further infliximab treatment, in patients not responding within 2 weeks to the initial infusion. In responding patients, the strategy for continued treatment is:

- Maintenance: Additional infusions of 5 mg/kg at 2 and 6 weeks after the initial dose, followed by infusions every eight weeks.

Fistulising Crohn's Disease
An initial 5 mg/kg infusion given over a 2-hour period is to be followed with additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion. If a patient does not respond after these 3 doses, no additional treatment with infliximab should be given.

In responding patients, the strategies for continued treatment are:
- Additional infusions of 5 mg/kg every 8 weeks or
- Readministration if signs and symptoms of the disease recur followed by infusions of 5 mg/kg every 8 weeks (see *Readministration* below and *Warnings and Precautions*).

Ulcerative Colitis
5mg/kg given as intravenous infusion over a 2 hour period followed by additional 5mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.

Available data suggest that the clinical response is usually achieved within 14 weeks of treatment, i.e. three doses. Continued therapy should be carefully reconsidered in patients who show no evidence of therapeutic benefit within this time period.

Ankylosing Spondylitis
5 mg/kg given as an intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 6 to 8 weeks. If a patient does not respond by 6 weeks (i.e. after 2 doses), no additional treatment with infliximab should be given.

Psoriatic Arthritis
5 mg/kg given as intravenous infusion over a 2-hour period followed by additional 5 mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. Efficacy and safety have been demonstrated in combination with methotrexate.

Psoriasis
5mg/kg given as intravenous infusion over a 2-hour period followed by additional 5mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. If a patient shows no response after 14 weeks (i.e. after 4 doses), no additional treatment with infliximab should be given.

Readministration for Crohn's Disease and Rheumatoid Arthritis
If the signs and symptoms of disease recur, REMICADE® can be readministered within 16 weeks following the last infusion. In clinical studies, delayed hypersensitivity reactions have been uncommon and have occurred after drug free intervals of less than 1 year (see *Warnings and Precautions* and *Adverse Reactions: Delayed Hypersensitivity*). After a drug free interval of 16 weeks to 2 years, the risk of delayed hypersensitivity following readministration is not known. Therefore, after a drug free interval of 16 weeks, readministration is not recommended.

Readministration for Ulcerative Colitis
The safety and efficacy of readministration, other than every 8 weeks, has not been established. (see *Warnings and Precautions* and *Adverse Reactions*).

Readministration for Ankylosing Spondylitis
The safety and efficacy of readministration, other than every 6 to 8 weeks, has not been established. (see *Warnings and Precautions* and *Adverse Reactions*).

Readministration for Psoriatic Arthritis
The safety and efficacy of readministration, other than every 8 weeks, has not been established. (see *Warnings and Precautions* and *Adverse Reactions*).

Readministration for Psoriasis
Limited experience from retreatment with one single infliximab dose in psoriasis after an interval of 20 weeks suggests reduced efficacy and a higher incidence of mild to moderate infusion reactions when compared to the initial induction regimen (see *Pharmacodynamic Properties*).

Special populations
Pediatrics (6-17 years of age)
REMICADE® has not been studied in children with Crohn's disease or ulcerative colitis < 6 years of age. The pharmacokinetics of REMICADE® has been evaluated in pediatric patients with Crohn's disease and ulcerative colitis (see *Pharmacokinetic Properties*). The safety and effectiveness of REMICADE® in pediatric patients with Juvenile Rheumatoid Arthritis, ankylosing spondylitis, psoriatic arthritis and plaque psoriasis have not been established.

Crohn's Disease
5mg/kg given as intravenous infusion over a 2-hour period followed by additional 5mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter. For some patients a longer dosing interval may be sufficient. Available data do not support further infliximab treatment in paediatric patients not responding within the first 10 weeks of treatment.

Pediatric Crohn's disease patients who have had their dose adjusted to greater than 5 mg/kg every 8 weeks, may be at greater risk for adverse reactions. Continued therapy with the adjusted dose should be carefully considered in patients who show no evidence of additional therapeutic benefit after dose adjustment.

Ulcerative Colitis
5mg/kg given as intravenous infusion over a 2 hour period followed by additional 5mg/kg infusion doses at 2 and 6 weeks after the first infusion, then every 8 weeks thereafter.

Renal Impairment
REMICADE® has not been studied in patients with renal impairment. No dose recommendations can be made (see *Pharmacokinetic Properties*).

Hepatic Impairment
REMICADE® has not been studied in patients with hepatic impairment. No dose recommendations can be made (see *Pharmacokinetic Properties*).

Administration
REMICADE® infusions should be administered by qualified healthcare professionals.

In order to improve the traceability of biological medicinal products, the trademark and the batch number of the administered product should be clearly recorded (or stated) in the patient file.

REMICADE® should be administered intravenously over a 2 hour period. All patients administered REMICADE® are to be observed for at least 1-2 hours post-infusion for acute infusion-related reactions. Emergency equipment, such as adrenaline, antihistamines, corticosteroids and an artificial airway must be available. Patients may be pre-treated with e.g.,

an antihistamine, hydrocortisone and/or paracetamol and infusion rate may be slowed in order to decrease the risk of infusion-related reactions especially if infusion-related reactions have occurred previously (see *Warnings and Precautions*).

Shortened Infusions across Adult Indications

In carefully selected adult patients who have tolerated at least 3 initial 2-hour infusions of REMICADE® (induction phase) and are receiving maintenance therapy, consideration may be given to administering subsequent infusions over a period of not less than 1 hour. If an infusion reaction occurs in association with a shortened infusion, a slower infusion rate may be considered for future infusions if treatment is to be continued. Shortened infusions at doses >6 mg/kg have not been studied.

For preparation and administration instructions, see *Instructions for Use and Handling and Disposal*.

Contraindications

REMICADE® is contraindicated in patients with tuberculosis or other severe infections such as sepsis, abscesses, and opportunistic infections (see *Warnings and Precautions*).

REMICADE® is contraindicated in patients with moderate or severe heart failure (NYHA class III/IV) (see *Warnings and Precautions* and *Adverse Reactions*).

REMICADE® must not be given to patients with a history of hypersensitivity to infliximab (see *Adverse Reactions*), to other murine proteins, or to any of the excipients.

Warnings and Precautions

Before starting treatment with REMICADE®, patients must be evaluated for both active and inactive ('latent') tuberculosis (see *Infections*).

REMICADE® should be used with caution in patients with mild heart failure (NYHA Class I/II) (see *Heart Failure*).

Infusion Reactions and Hypersensitivity

Infliximab has been associated with acute infusion-related reactions, including, anaphylactic shock, and delayed hypersensitivity reactions (see *Adverse Reactions*). To minimize the incidence of hypersensitivity reactions, including infusion reactions and serum sickness-like reactions, REMICADE® should be administered as regular maintenance therapy after an induction regimen at weeks 0, 2 and 6 (see *Dosage and Administration*).

Acute infusion reactions including anaphylactic reactions may develop during (within seconds) or within a few hours following infusion. If acute infusion reactions occur, the infusion must be interrupted immediately. Emergency equipment, such as adrenaline, antihistamines, corticosteroids and an artificial airway must be available. Patients may be pretreated with e.g., an antihistamine, hydrocortisone and/or paracetamol to prevent mild and transient effects.

Antibodies to infliximab may develop and have been associated with an increased frequency of infusion reactions. A low proportion of the infusion reactions were serious allergic reactions. In Crohn's disease patients, an association between development of antibodies to infliximab and reduced duration of response has also been observed. Concomitant administration of immunomodulators has been associated with lower incidence of antibodies to infliximab and a reduction in the frequency of infusion reactions. The effect of concomitant immunomodulator therapy was more profound in episodically treated patients than in patients given maintenance

therapy. Patients who discontinue immunosuppressants prior to or during REMICADE® treatment are at greater risk of developing these antibodies. Antibodies to infliximab cannot always be detected in serum samples. If serious reactions occur, symptomatic treatment must be given and further REMICADE® infusions must not be administered (see *Adverse Reactions: "Immunogenicity"*).

In clinical trials, delayed hypersensitivity reaction has been reported. Available data suggest an increased risk for delayed hypersensitivity with increasing drug free interval. Advise patients to seek immediate medical advice if they experience any delayed adverse event (see *Adverse Reactions: "Delayed hypersensitivity"*). If patients are retreated after a prolonged period, they must be closely monitored for signs and symptoms of delayed hypersensitivity.

Infusion reactions following re-administration of REMICADE®

In a psoriasis clinical trial, a 3-dose re-induction of REMICADE® after a period of no treatment resulted in a higher incidence of serious infusion reactions during the re-induction regimen (see *Adverse Reactions*) than had been observed in rheumatoid arthritis, psoriasis, and Crohn's disease trials in which a period of no drug treatment was followed by regular maintenance therapy without re-induction.

In the case where REMICADE® maintenance therapy for psoriasis is interrupted, REMICADE® should be reinitiated as a single dose followed by maintenance therapy.

In general, the benefit-risk of re-administration of REMICADE® after a period of no-treatment, especially as a re-induction regimen given at weeks 0, 2, and 6, should be carefully considered.

Infections

Patients must be monitored closely for infections including tuberculosis before, during and after treatment with REMICADE®. Because the elimination of infliximab may take up to six months, monitoring should be continued throughout this period. Further treatment with REMICADE® must not be given if a patient develops a serious infection or sepsis.

REMICADE® should not be given to patients with a clinically important, active infection. Caution should be exercised when considering the use of REMICADE® in patients with chronic infection or a history of recurrent infections, including use of concomitant immunosuppressive medications. Patients should be advised of and avoid exposure to potential risk factors for infection as appropriate.

Tumour necrosis factor alpha (TNFα) mediates inflammation and modulates cellular immune responses. Experimental data show that TNFα is essential for the clearing of intracellular infections. Clinical experience shows that host defence against infection is compromised in some patients treated with infliximab.

It should be noted that suppression of TNFα may also mask symptoms of infection such as fever. Early recognition of atypical clinical presentations of serious infections is critical in order to minimize delays in diagnosis and treatment.

Patients taking TNF-blockers are more susceptible to serious infections. Mycobacterial [including tuberculosis (frequently disseminated or extrapulmonary at clinical presentation)], viral infections, bacterial infections, including sepsis and pneumonia, invasive fungal infections, and other opportunistic infections have been observed in patients treated with infliximab. Some of these infections have been fatal. Opportunistic infections reported in patients on REMICADE® have included, but are not limited to pneumocystosis, histoplasmosis,

cytomegalovirus infection, atypical mycobacterial infections, listeriosis and aspergillosis. In clinical trials, infections have been reported more frequently in paediatric patient populations than in adult populations (see *Adverse Reactions*).

Tuberculosis

Before starting treatment with REMICADE®, all patients must be evaluated for both active and inactive ('latent') tuberculosis. This evaluation should include a detailed medical history with personal history of tuberculosis or possible previous contact with tuberculosis and previous and/or current immunosuppressive therapy. Appropriate screening tests, i.e. tuberculin skin test and chest x-ray, should be performed in all patients (local recommendations may apply). Prescribers are reminded of the risk of false negative tuberculin skin test results especially in patients who are severely ill or immunocompromised.

If active tuberculosis is diagnosed, REMICADE® therapy must not be initiated (see *Contraindications*)

If inactive ('latent') tuberculosis is diagnosed, prophylactic anti-tuberculosis therapy must be started before the initiation of REMICADE®, and in accordance with local recommendations. In this situation, the benefit/ risk balance of REMICADE® therapy should be very carefully considered.

In patients who have several or significant risk factors for tuberculosis and have a negative test for latent tuberculosis, anti-tuberculosis therapy should be considered before the initiation of REMICADE®. Use of anti-tuberculosis therapy should also be considered before the initiation of REMICADE® in patients with a past history of latent or active tuberculosis in whom an adequate course of treatment cannot be confirmed.

Use of anti-tuberculosis therapy should be considered before the initiation of REMICADE® in patients who have several or highly significant risk factors for tuberculosis infection and have a negative test for latent tuberculosis.

The decision to initiate anti-tuberculosis therapy in these patients should only be made following consultation with a physician with expertise in the treatment of tuberculosis and taking into account both the risk for latent tuberculosis infection and the risks of anti-tuberculosis therapy.

Cases of active tuberculosis have occurred in patients treated with REMICADE® during and after treatment for latent tuberculosis. Cases of active tuberculosis including miliary tuberculosis and tuberculosis with extrapulmonary location have been reported in patients treated with REMICADE®.

All patients should be informed to seek medical advice if signs / symptoms suggestive of tuberculosis (e.g. persistent cough, wasting / weight loss, low-grade fever) appear during or after REMICADE® treatment.

Invasive Fungal Infections

For patients who have resided in or traveled to regions where invasive fungal infections such as histoplasmosis, coccidioidomycosis, or blastomycosis are endemic, the benefits and risks of REMICADE® treatment should be carefully considered before initiation or continuation of REMICADE® therapy.

In patients treated with REMICADE®, an invasive fungal infection such as aspergillosis, candidiasis, pneumocystosis, histoplasmosis, coccidioidomycosis or blastomycosis should be suspected if they develop a serious systemic illness. Invasive fungal infections may present as disseminated rather than localized disease, and antigen and antibody testing may be negative in some patients with active infection. Appropriate empiric antifungal therapy should be considered while a diagnostic workup is being performed. The decision to administer empiric antifungal therapy should be made, if feasible, in consultation with a physician with expertise in the diagnosis and treatment of invasive fungal infections and should take into account both the risk for severe fungal infection and the risks of anti-fungal therapy.

Fistulising Crohn's disease

Patients with fistulising Crohn's disease with acute suppurative fistulas must not initiate REMICADE® therapy until a source for possible infection, specifically abscess, has been excluded (see *Contraindications*).

Hepatitis B Reactivation

Reactivation of hepatitis B has occurred in patients receiving a TNF-antagonist including REMICADE®, who are chronic carriers of this virus. Some cases have had fatal outcome. Patients at risk for HBV infection should be evaluated for prior evidence of HBV infection before initiating REMICADE® therapy. Carriers of HBV who require treatment with REMICADE® should be closely monitored for signs and symptoms of active HBV infection throughout therapy and for several months following termination of therapy. Adequate data of treating patients who are carriers of HBV with anti-viral therapy in conjunction with TNF-antagonist therapy to prevent HBV reactivation are not available. In patients who develop HBV reactivation, REMICADE® should be stopped and effective anti-viral therapy with appropriate supportive treatment should be initiated. Patients should be tested for Hepatitis B Virus (HBV) infection before initiating treatment with immunosuppressants, including REMICADE®. For patients who test positive for hepatitis B surface antigen, consultation with a physician with expertise in the treatment of hepatitis B is recommended.

Hepatobiliary Events

Cases of jaundice and non-infectious hepatitis, some with features of autoimmune hepatitis, have been observed in the post-marketing experience of REMICADE®. Isolated cases of liver failure resulting in liver transplantation or death have occurred. A causal relationship between REMICADE® and these events has not been established. Patients with symptoms or signs of liver dysfunction should be evaluated for evidence of liver injury. If jaundice and/or ALT elevations ≥ 5 times the upper limit of normal develops, REMICADE® should be discontinued, and a thorough investigation of the abnormality should be undertaken.

Concurrent Administration of TNF-alpha Inhibitor and Anakinra

Serious infections and neutropenia were seen in clinical studies with concurrent use of anakinra and another TNFα-blocking agent, etanercept, with no added clinical benefit compared to etanercept alone. Because of the nature of the adverse events seen with combination of etanercept and anakinra therapy, similar toxicities may also result from the combination of anakinra and other TNFα-blocking agents. Therefore, the combination of REMICADE® and anakinra is not recommended.

Concurrent Administration of TNF-alpha Inhibitor and Abatacept

In clinical studies, concurrent administration of TNF-blocking agents and abatacept have been associated with an increased risk of infections including serious infections compared with TNF-blocking agents alone, without increased clinical benefit. Because of the nature of the adverse

events seen with the combination of TNF-blocking agents and abatacept therapy, the combination of infliximab and abatacept is not recommended.

Concurrent Administration with Other Biological Therapeutics

There is insufficient information regarding the concomitant use of REMICADE® with other biological therapeutics used to treat the same conditions as REMICADE®. The concomitant use of REMICADE® with these biologics is not recommended because of the possibility of an increased risk of infection and other potential pharmacological interactions.

Switching Between Biological DMARDS

When switching from one biologic to another, patients should continue to be monitored, since overlapping biological activity may further increase the risk of infection.

Vaccinations

It is recommended that all patients, if possible, be brought up to date with all vaccinations in agreement with current vaccination guidelines prior to initiating REMICADE® therapy.

Live Vaccines/Therapeutic Infectious Agents

In patients receiving anti-TNF therapy, limited data are available on the response to vaccination with live vaccines or on the secondary transmission of infection by live vaccines. Use of live vaccines can result in clinical infections, including disseminated infections. The concurrent administration of live vaccines with REMICADE® is not recommended.

Infant Exposure *In Utero*

Fatal outcome due to disseminated Bacille Calmette-Guérin (BCG) infection has been reported in an infant who received BCG vaccine after *in utero* exposure to infliximab. A twelve month waiting period following birth is recommended before the administration of live vaccines to infants exposed *in utero* to infliximab, unless infliximab exposure was limited to the first trimester or if infant infliximab serum levels are undetectable. Administration of a live vaccine prior to 12 months of age might be considered if the benefit of the vaccination clearly outweighs the theoretical risk of administration of live vaccines to the infants (see *Pregnancy*, *Breast-feeding and Fertility*).

Infant Exposure Via Breast Milk

Administration of a live vaccine to a breastfed infant while the mother is receiving infliximab is not recommended unless infant infliximab serum levels are undetectable (see *Pregnancy, Breast-feeding and Fertility*).

Therapeutic Infectious Agents

Other uses of therapeutic infectious agents such as live attenuated bacteria (e.g., BCG bladder instillation for the treatment of cancer) could result in clinical infections, including disseminated infections. It is recommended that therapeutic infectious agents not be given concurrently with REMICADE®.

Non-live Vaccines

In a subset of patients from the ASPIRE study, a similar proportion of patients in each treatment group mounted an effective two fold increase in titers to a polyvalent pneumococcal vaccine, indicating that REMICADE® did not interfere with T cell independent humoral immune responses.

Autoimmune Processes

The relative deficiency of TNFα caused by anti-TNF therapy may result in the initiation of an autoimmune process. If a patient develops symptoms suggestive of a lupus-like syndrome following treatment with REMICADE® and is positive for antibodies against double-stranded DNA, further treatment with REMICADE® must not be given. (see *Adverse Reactions, Antinuclear Antibodies (ANA)/Anti-Double-Stranded DNA (dsDNA) Antibodies*)

Neurological Events

Infliximab and other agents that inhibit TNFα have been associated with seizure and new onset or exacerbation of clinical symptoms and/or radiographic evidence of central nervous system demyelinating disorders, including multiple sclerosis and optic neuritis and peripheral demyelinating disorders, including Guillain-Barré syndrome (see *Adverse Reactions*). Prescribers should exercise caution in considering the use of REMICADE® in patients with these neurologic disorders and should consider discontinuation of REMICADE® if these disorders develop.

Malignancies and Lymphoproliferative Disorders

In the controlled portions of clinical trials of all the TNF-blocking agents, more cases of malignancies including lymphoma have been observed among patients receiving a TNF blocker compared with control patients. During clinical trials of REMICADE® across all approved indications, the incidence of lymphoma in REMICADE®-treated subjects was higher than expected in the general population, but the occurrence of lymphoma was rare. Patients with Crohn's disease or rheumatoid arthritis, particularly patients with highly active disease and/or chronic exposure to immunosuppressant therapies, may be at a higher risk (up to several fold) than the general population for the development of lymphoma, even in the absence of TNF blocking therapy.

Non-lymphoma Malignancy

In an exploratory clinical trial evaluating the use of REMICADE® in patients with moderate to severe chronic obstructive pulmonary disease (COPD), more malignancies were reported in REMICADE®-treated patients compared with control patients. All patients had a history of heavy smoking. Caution should be exercised in considering treatment of patients with increased risk of malignancy due to heavy smoking.

Caution should also be exercised in patients with psoriasis and a medical history of extensive immunosuppressant therapy or prolonged PUVA treatment.

Psoriasis patients should be monitored for non-melanoma skin cancers (NMSCs), particularly those patients who have had prior prolonged phototherapy treatment.

Pediatric Malignancy

Post-marketing cases of malignancies, some fatal, have been reported among children, adolescents and young adults (up to 22 years of age) who received TNF-blocking agents (initiation of therapy ≤ 18 years of age), including REMICADE®, to treat Juvenile Idiopathic Arthritis (JIA), Crohn's disease or other conditions. Approximately half the reports were lymphomas. The other cases represented a variety of different malignancies and included malignancies that are not usually observed in children and adolescents. Most of the patients were receiving concomitant immunosuppressants, such as methotrexate, azathioprine or 6-mercaptopurine. The role of TNF blockers in the development of malignancies in children and adolescents remains unclear.

Hepatosplenic T-cell Lymphoma

Post-marketing cases of hepatosplenic T-cell lymphoma have been reported in patients treated with TNF-blocking agents including REMICADE®. This rare type of T-cell lymphoma has a very aggressive disease course and is usually fatal. Almost all patients had received treatment with azathioprine or 6-mercaptopurine concomitantly with or immediately prior to a TNF-blocker. The vast majority of REMICADE® cases have occurred in patients with Crohn's disease or ulcerative colitis and most were reported in adolescent or young adult males. Cases of hepatosplenic T-cell lymphoma have also occurred in Crohn's disease patients and ulcerative colitis patients receiving azathioprine or 6-mercaptopurine who were not treated with REMICADE®. Before initiating or continuing REMICADE® therapy in a patient who is receiving an immunosuppressant such as azathioprine or 6-mercaptopurine, the need for continuing the immunosuppressant therapy should be carefully assessed in light of the potential risks of concomitant therapy. The causal relationship of hepatosplenic T-cell lymphoma to REMICADE® therapy remains unclear.

A risk for the development for hepatosplenic T-cell lymphoma in patients treated with REMICADE® cannot be excluded (see *Dosage and Administration* and *Adverse Reactions*).

All patients with ulcerative colitis who are at increased risk for dysplasia or colon carcinoma (for example, patients with long-standing ulcerative colitis or primary sclerosing cholangitis), or who had a prior history of dysplasia or colon carcinoma should be screened for dysplasia at regular intervals before the therapy and throughout their disease course. This evaluation should include colonoscopy and biopsies per local recommendations. With current data it is not known if infliximab treatment influences the risk for developing dysplasia or colon cancer (see *Adverse Reactions*).

Since the possibility of increased risk of cancer development in patients with newly diagnosed dysplasia treated with REMICADE® is not established, the risk and benefits to the individual patients must be carefully reviewed and consideration should be given to discontinuation of therapy.

Leukemia

Cases of acute and chronic leukemia have been reported with post-marketing TNF-blocker use in rheumatoid arthritis and other indications. Even in the absence of TNF blocker therapy, patients with rheumatoid arthritis may be at a higher risk (approximately 2-fold) than the general population for the development of leukemia.

Skin Cancers

Melanoma and Merkel cell carcinoma have been reported in patients treated with TNF blocker therapy, including REMICADE® (see *Adverse Reactions*). Periodic skin examination is recommended for all patients, particularly those with risk factors for skin cancer.

Cervical Cancer

A population-based retrospective cohort study using data from Swedish national health registries found an increased incidence of cervical cancer in women with rheumatoid arthritis treated with infliximab compared to biologics-naïve patients or the general population, including those over 60 years of age. A causal relationship between infliximab and cervical cancer cannot be excluded. Periodic screening should continue in women treated with REMICADE®, including those over 60 years of age.

The potential role of TNF-blocking therapy in the development of malignancies is not known. With the current knowledge, a risk for the development of lymphomas or other malignancies in

patients treated with a TNF-blocking agent cannot be excluded (see *Adverse Reactions*). Caution should be exercised when considering TNF-blocking therapy for patients with history of malignancy or when considering continuing treatment in patients who develop a malignancy.

Congestive Heart Failure
REMICADE® should be used with caution in patients with mild heart failure (NYHA class I/II). Patients should be closely monitored and REMICADE® must not be continued in patients who develop new or worsening symptoms of heart failure (see *Contraindications* and *Adverse Reactions*).

Hematologic Events
Cases of leukopenia, neutropenia, thrombocytopenia, and pancytopenia, some with a fatal outcome, have been reported in patients receiving REMICADE®. The causal relationship to REMICADE® therapy remains unclear. Although no high-risk group(s) has been identified, caution should be exercised in patients being treated with REMICADE® who have ongoing or a history of significant hematologic abnormalities. All patients should be advised to seek immediate medical attention if they develop signs and symptoms suggestive of blood dyscrasias or infection (e.g. persistent fever) while on REMICADE®. Discontinuation of REMICADE® therapy should be considered in patients who develop significant hematologic abnormalities.

Pediatrics
REMICADE® has not been studied in patients with Crohn's disease or ulcerative colitis below the age of 6 years.

The pharmacokinetics of infliximab in elderly patients has not been studied. The incidence of serious infections in REMICADE®-treated patients 65 years and older was greater than in those under 65 years of age. In addition, there is a greater incidence of infections in the elderly population in general, therefore, caution should be used in treating the elderly.

Others
Studies have not been performed in patients with liver or renal disease (see *Pharmacokinetic Properties*).

There are insufficient preclinical data to draw conclusions on the effects of infliximab on fertility and general reproductive function (see *Non-Clinical Information*).

There is limited safety experience of surgical procedures in REMICADE® treated patients. The long half-life of REMICADE® should be taken into consideration if a surgical procedure is planned. A patient who requires surgery while on REMICADE® should be closely monitored for infections, and appropriate actions should be taken.

There is limited safety experience of REMICADE® treatment in patients who have undergone arthroplasty.

Treatment of patients with intestinal strictures due to Crohn's disease is not recommended since the risk/benefit relationship in this patient population has not been established.

Biosimilar Interchangeability
The safety and efficacy of alternating or switching between REMICADE® and products that are biosimilar but not deemed interchangeable to REMICADE® has not been established. Therefore, alternating or switching between REMICADE® and products that are biosimilar cannot be recommended.

Interactions

Specific drug interaction studies have not been conducted with REMICADE®.

In rheumatoid arthritis and Crohn's disease patients, there are indications that concomitant use of methotrexate and other immunomodulators reduces the formation of antibodies against infliximab and increases the plasma concentrations of infliximab. However, the results are uncertain due to limitations in the methods used for serum analyses of infliximab and antibodies against infliximab.

Corticosteroids do not appear to affect the pharmacokinetics of infliximab to a clinically relevant extent.

The combination of REMICADE® with other biological therapeutics used to treat the same conditions as REMICADE®, including anakinra and abatacept, is not recommended (see *Warnings and Precautions*).

Live Vaccines/Therapeutic Infectious Agents

It is recommended that live vaccines not be given concurrently with REMICADE®. It is also recommended that live vaccines not be given to infants after *in utero* exposure to infliximab for 12 months following birth, unless infliximab exposure was limited to the first trimester or if infant infliximab serum levels are undetectable. Administration of a live vaccine prior to 12 months of age might be considered if the benefit of the vaccination clearly outweighs the theoretical risk of administration of live vaccines to the infants (see *Warnings and Precautions*).

Administration of a live vaccine to a breastfed infant while the mother is receiving infliximab is not recommended unless infant infliximab serum levels are undetectable (see *Warnings and Precautions and Pregnancy, Breast-feeding and Fertility*).

It is recommended that therapeutic infectious agents not be given concurrently with REMICADE® (see *Warnings and Precautions*).

Pregnancy, Breast-feeding and Fertility

Pregnancy

Available observational studies in pregnant women exposed to REMICADE® showed no increased risk of major malformations among live births as compared to those exposed to non-biologics. However, findings on other birth outcomes were not consistent across the studies. In one study conducted in a North America IBD pregnancy registry, REMICADE® exposure was not associated with increased rates of miscarriage/stillbirth, low birth weight, small for gestational age, or infant infection in the first year of life as compared to exposure to non-biologics [Maternal exposure to REMICADE®, Maternal exposure to Non-biologics: 294, 515]. In another study in Northern Europe among IBD and non-IBD patients, exposure to REMICADE® in combination with immunosuppressants (mainly systemic corticosteroids and azathioprine), but not REMICADE® as monotherapy, was associated with increased rates of preterm birth, small for gestational age, low birth weight, and infant hospitalization for infection compared with non-biologic systemic treatment [Live births with maternal exposure to REMICADE®, Live births with maternal exposure to Non-biologics: 270, 6460]. Both studies have potential for confounding (e.g., the concomitant use of other medications or treatments was not controlled and disease severity was not assessed). REMICADE® should be given to a pregnant woman only if clearly needed.

It is not known whether REMICADE® can affect reproductive potential.

Since REMICADE® does not cross-react with TNFα in species other than humans and chimpanzees, animal reproduction studies have not been conducted with REMICADE®. No evidence of maternal toxicity, embryotoxicity or teratogenicity was observed in a developmental toxicity study conducted in mice using an analogous antibody that selectively inhibits the functional activity of mouse TNFα. Doses of 10 to 15 mg/kg in pharmacodynamic animal models with the anti-TNF analogous antibody produced maximal pharmacologic effectiveness. Doses up to 40 mg/kg were shown to produce no adverse effects in animal reproduction studies.

Women of childbearing potential should use adequate contraception to prevent pregnancy and continue its use for at least 6 months after the last REMICADE® treatment.

As with other IgG antibodies, infliximab crosses the placenta. Infliximab has been detected in the serum of infants up to 12 months following birth. The clinical significance of low serum levels of infliximab on the immune status in infants is unknown.

After *in utero* exposure to infliximab, infants may be at increased risk of infection, including disseminated infection that can become fatal (see *Warnings and Precautions*).

Breast-feeding
REMICADE® has been detected at low levels in human milk and in infant serum via breast milk. While systemic exposure in a breastfed infant is expected to be low because infliximab is largely degraded in the gastrointestinal tract, the administration of live vaccines to a breastfed infant when the mother is receiving infliximab is not recommended unless infant infliximab serum levels are undetectable. Limited data from published literature reported that infants exposed to infliximab through breast milk had no increase in rates of infections and developed normally. The consideration of REMICADE® use during breast-feeding should take into account the importance of the drug to the mother and health benefits of breast-feeding for the infant.

Fertility
The effect of infliximab on human fertility has not been evaluated.

Effects on Ability to Drive and Use Machines
No studies on the effects on the ability to drive and use machines have been performed.

Adverse Reactions
Adverse reactions are adverse events that were considered to be reasonably associated with the use of infliximab based on the comprehensive assessment of the available adverse event information. A causal relationship with infliximab cannot be reliably established in individual cases. Further, because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

In clinical studies with infliximab, adverse reactions were observed in approximately 60% of infliximab-treated patients and 40% of placebo-treated patients. The adverse reactions listed in Table 1 are based on experience from clinical trials. Within the organ system classes, adverse reactions are listed under the headings of frequency using the following categories: common (> 1/100, < 1/10); uncommon (> 1/1000, < 1/100); rare (>1/10,000, <1/1000). Infusion-related reactions were the most common adverse reactions reported. Infusion-related reactions (dyspnoea, urticaria and headache) were the most common cause for discontinuation.

Table 1: Adverse Reactions in Clinical Studies

Infections and Infestations		
	Common:	Viral infection (e.g. influenza, herpes infections)
	Uncommon:	Abscess, cellulitis, moniliasis, sepsis, bacterial infection, tuberculosis, fungal infection, hordeolum
Neoplasms benign, malignant and unspecified		
	Uncommon:	Basal cell carcinoma, squamous cell carcinoma
	Rare:	Lymphoma
Immune system disorders		
	Common:	Serum sickness-like reactions
	Uncommon:	Lupus-like syndrome, respiratory tract allergic reactions, anaphylactic reactions
	Rare:	Sarcoid-like reaction
Blood and lymphatic disorders		
	Uncommon:	Anemia, leukopenia, lymphadenopathy, lymphocytosis, lymphopenia, neutropoenia, thrombocytopenia
Psychiatric disorders		
	Uncommon:	Depression, confusion, agitation, amnesia, apathy, nervousness, somnolence, insomnia
Nervous system disorders		
	Common:	Headache, vertigo/dizziness
	Uncommon:	Exacerbation of demyelinating disease suggestive of multiple sclerosis
	Rare:	Meningitis
Eye disorders		
	Uncommon:	Conjunctivitis, endophthalmitis, keratoconjunctivitis, periorbital edema
Cardiac disorders		
	Uncommon:	Syncope, bradycardia, palpitation, cyanosis, arrhythmia, worsening heart failure
	Rare:	Tachycardia
Vascular disorders		
	Common:	Flushing
	Uncommon:	Ecchymosis/hematoma, hot flushes, hypertension, hypotension, petechia, thrombophlebitis, vasospasm, peripheral ischaemia
	Rare:	Circulatory failure
Respiratory, thoracic and mediastinal disorders		
	Common:	Upper respiratory tract infection, lower respiratory tract infection (e.g. bronchitis, pneumonia), dyspnoea, sinusitis
	Uncommon:	Epistaxis, bronchospasm, pleurisy, pulmonary oedema
	Rare:	Pleural effusion
Gastro-intestinal system		
	Common:	Nausea, diarrhea, abdominal pain, dyspepsia, vomiting
	Uncommon:	Constipation, gastroesophageal reflux, cheilitis, diverticulitis
	Rare:	Intestinal perforation, intestinal stenosis, gastrointestinal hemorrhage
Hepatobiliary disorders		
	Common:	Abnormal hepatic function, cholecystitis
	Rare:	Hepatitis
Skin and subcutaneous tissue disorders		
	Common:	Rash, pruritus, urticaria, increased sweating, dry skin
	Uncommon:	Fungal dermatitis/ onychomycosis, eczema/ seborrhea, bullous eruption, furunculosis, hyperkeratosis, rosacea, verruca, abnormal skin pigmentation/coloration, alopecia
Musculoskeletal and connective tissue disorders		
	Uncommon:	Myalgia, arthralgia, back pain
Renal and urinary disorders		
	Uncommon:	Urinary tract infection, pyelonephritis
Reproductive system and breast disorders		
	Uncommon:	Vaginitis

General disorders and administration site conditions		
	Common:	Fatigue, chest pain, infusion-related reactions, fever
	Uncommon:	Injection site reactions, edema, pain, chills/rigors, impaired healing
	Rare:	Granulomatous lesion
Investigations		
	Common:	Elevated hepatic transaminases
	Uncommon:	Autoantibodies, complement factor abnormality

Table 2: Adverse Reactions in Post-marketing reports

(common > 1/100, < 1/10; uncommon > 1/1000, < 1/100;
rare > 1/10,000, < 1/1000; very rare <1/10,000, including isolated reports)

Nervous system disorders		
	Rare:	Central nervous system demyelinating disorders (such as multiple sclerosis and optic neuritis), peripheral demyelinating disorders (such as Guillain-Barré syndrome, chronic inflammatory demyelinating polyneuropathy, and multifocal motor neuropathy), neuropathies, numbness, tingling, seizure, cerebrovascular accidents occurring within approximately 24 hours of initiation of infusion
	Very rare:	Transverse myelitis, orbital apex syndrome
Blood and lymphatic system disorders		
	Rare:	Pancytopenia
	Very rare:	Hemolytic anemia, idiopathic thrombocytopenia purpura, thrombotic thrombocytopenic purpura, agranulocytosis (including infants exposed *in utero* to infliximab)
Neoplasms benign, malignant and unspecified (including cysts and polyps)		
	Rare:	Hepatosplenic T-cell lymphoma (the vast majority in Crohn's Disease and ulcerative colitis: primarily adolescents and young adults), lymphoma (including non-Hodgkin's lymphoma and Hodgkin's Disease), leukemia, melanoma, cervical cancer
	Very Rare:	Pediatric malignancy, Merkel cell carcinoma,
Immune system disorders		
	Uncommon:	Anaphylactic reactions
	Rare:	Anaphylactic shock, serum sickness, vasculitis
Cardiac disorders		
	Rare:	Worsening heart failure, new onset heart failure
	Very rare:	Pericardial effusion
Infections and infestations		
	Uncommon:	Sepsis
	Rare:	Opportunistic infections (such as tuberculosis, atypical mycobacteria, pneumocystis carinii pneumonia (PCP), pneumocystosis, histoplasmosis, coccidioidomycosis, aspergillosis, listeriosis and candidiasis, cryptococcosis)
	Very rare:	Salmonellosis, hepatitis B reactivation, protozoal infection, and vaccine breakthrough infection (after *in utero* exposure to infliximab)*
Respiratory, thoracic and mediastinal disorders		
	Rare:	Interstitial lung disease, including pulmonary fibrosis/interstitial pneumonitis
	Very rare:	Rapidly progressive interstitial lung disease
Gastrointestinal disorders		
	Rare:	Pancreatitis
Hepatobiliary disorders		
	Rare:	Hepatitis
	Very rare:	Hepatocellular damage, jaundice, autoimmune hepatitis, liver failure

Skin and subcutaneous tissue disorders	
Rare:	Vasculitis (primarily cutaneous), acute generalized exanthematous pustulosis (AGEP), lichenoid reactions
Very rare:	Toxic epidermal necrolysis, Stevens-Johnson-Syndrome, erythema multiforme, psoriasis including new onset and pustular (primarily palmar/plantar), linear IgA bullous dermatosis (LABD)
General disorders and administration site conditions	
Common:	Infusion-related reactions

* including bovine tuberculosis (disseminated BCG infection), see *Warnings and Precautions.*

Transient visual loss occurring during or within 2 hours of REMICADE® infusion have also been reported.

Myocardial ischemia/myocardial infarction and arrhythmia within 24 hours of initiation of infusion have also been reported.

Hemophagocytic lymphohistiocytosis (HLH) has been very rarely reported in patients treated with REMICADE®.

Infusion-Related Reactions

An infusion-related reaction was defined in clinical trials as any adverse event occurring during an infusion or within 1 hour after an infusion.

In phase 3 clinical studies, 18% of infliximab-treated patients compared with 5% of placebo-treated patients experienced an infusion-related reaction. Of infliximab-treated patients who had an infusion reaction during the induction period, 27% experienced an infusion reaction during the maintenance period, week 7 through week 54. Of patients who did not have an infusion reaction during the induction period, 9% experienced an infusion reaction during the maintenance period.

Approximately 3% of patients discontinued treatment due to infusion-related reactions, and all patients recovered with or without medical therapy.

In a clinical study of patients with rheumatoid arthritis (ASPIRE), study medication was administered to each patient by infusion over 2 hours for the first 3 study infusions. For patients who did not experience a serious infusion reaction with the first 3 study infusions, subsequent infusions could be shortened to not less than 40 minutes. Sixty six percent of the patients (686 out of 1040) received at least one shortened infusion of 90 minutes or less and 44% of the patients (454 out of 1040) received at least one shortened infusion of 60 minutes or less. Of the REMICADE®-treated patients who received at least one shortened infusion, infusion-related reactions occurred in 15% (74/494) of patients and serious infusion reactions occurred in 0.4% (2/494) of patients. Shortened infusions at doses > 6 mg/kg have not been studied.

In Phase 3 clinical studies, in patients receiving infliximab with or without concomitant immunomodulator therapy, 13-19% of patients receiving infliximab at a low infusion rate (≤ 6 mg/kg/2-hr) experienced an infusion-related reaction, compared to 15-16% of patients receiving infliximab at a high infusion rate (> 6 mg/kg/2-hr or equivalent to >3 mg/kg/1-hr). Of patients receiving infliximab at a low infusion rate, 0.4%-0.7% experienced a serious infusion-related reaction, compared to 0.4%-0.5% of patients receiving infliximab at a high infusion rate.

In a clinical study of patients with Crohn's disease (SONIC), infusion-related reactions occurred in 16.6% (27/163) of patients receiving REMICADE® monotherapy, 5.0% (9/179) of patients receiving REMICADE® in combination with azathioprine, and 5.6% (9/161) of patients

receiving azathioprine monotherapy. One patient experienced a serious infusion reaction with REMICADE® monotherapy.

In post-marketing surveillance, reports of anaphylactic-like reactions, including laryngeal/pharyngeal edema, severe bronchospasm, and seizure have been associated with REMICADE® administration. Cases of transient visual loss occurring during or within 2 hours of REMICADE® infusion have been reported. Cerebrovascular accidents, myocardial ischemia/myocardial infarction (some fatal), and arrhythmia occurring within 24 hours of initiation of infusion have also been reported.

Infusion reactions following re-administration of REMICADE®

In rheumatoid arthritis, Crohn's disease, and psoriasis clinical trials, re-administration of REMICADE® after a period of no treatment resulted in a higher incidence of infusion reactions relative to regular maintenance treatment.

A clinical study in patients with moderate to severe psoriasis was designed to assess the efficacy and safety of long-term maintenance therapy versus re-treatment with an induction regimen of REMICADE® (maximum of four infusions at 0, 2, 6 and 14 weeks) following disease flare. Patients did not receive any concomitant immunosuppressant therapy. In the re-treatment arm, 4% (8/219) of patients experienced a serious infusion reaction versus < 1% (1/222) on maintenance therapy. The majority of serious infusion reactions occurred during the second infusion at Week 2. The interval between the last maintenance dose and the first re-induction dose ranged from 35-231 days. Symptoms included, but were not limited to, dyspnea, urticaria, facial edema, and hypotension. In all cases, REMICADE® treatment was discontinued and/or other treatment instituted with complete resolution of signs and symptoms.

Delayed Hypersensitivity

In a study where 37 of 41 patients with Crohn's disease were retreated with REMICADE® following a 2 to 4 year period without REMICADE® treatment, 10 patients experienced adverse events manifesting 3 to 12 days following infusion of which 6 were considered serious. Signs and symptoms included myalgia and/or arthralgia with fever and/or rash, with some patients also experiencing pruritus, facial, hand or lip edema, dysphagia, urticaria, sore throat, and headache. Patients experiencing these adverse events had not experienced infusion-related adverse events associated with their initial REMICADE® therapy. These adverse events occurred in 39% (9/23) of patients who had received liquid formulation which is no longer in use and 7% (1/14) of patients who received lyophilized formulation. The clinical data are not adequate to determine if occurrence of these reactions is due to differences in formulation. Patients' signs and symptoms improved substantially or resolved with treatment in all cases. There are insufficient data on the incidence of these events after drug-free intervals of 1 to 2 years. These events have been observed only infrequently in clinical studies and post-marketing surveillance with re-treatment intervals up to 1 year. In the 3 psoriasis studies, 1% (15/1373) of patients experienced symptoms of arthralgia, serum sickness, myalgia, fever and rash. When these occurred, they were often early in the treatment course following REMICADE® infusions. REMICADE® treatment was discontinued and/or other treatment instituted in most cases with improvement or resolution of signs and symptoms.

In a 1-year trial with repeated infusions in patients with Crohn's disease (ACCENT I study), the incidence of serum sickness-like reactions was 2.4%.

Immunogenicity

Patients who developed antibodies to infliximab were more likely (approximately 2-3 fold) to develop infusion-related reactions. Antibodies to REMICADE® occurred in approximately

10% of patients given a 3-dose induction regimen followed by maintenance dosing. Use of concomitant immunosuppressant agents appeared to reduce the frequency of antibodies to infliximab and infusion-related reactions.
In clinical studies using single and multiple infliximab doses ranging from 1 to 20 mg/kg, antibodies to infliximab were detected in 140 of 980 (14%) patients with any immunosuppressant therapy, and in 92 of 383 (24%) patients without immunosuppressant therapy. In rheumatoid arthritis patients who received the recommended repeated treatment dose regimens with methotrexate, 6 of 77 (8%) patients developed antibodies to infliximab. In Crohn's disease patients who received maintenance treatment, antibodies to infliximab occurred overall in 3.3% of patients receiving immunosuppressants and in 13.3% of patients not receiving immunosuppressants. The antibody incidence was 2-3 folds higher for patients treated episodically. Due to methodological limitations, a negative assay did not exclude the presence of antibodies to infliximab. Some patients who developed high titres of antibodies to infliximab had evidence of reduced efficacy (see *Warnings and Precautions: "Infusion Reactions and Hypersensitivity"*). In psoriasis patients treated with infliximab as a maintenance regimen in the absence of concomitant immunomodulators, approximately 28% developed antibodies to infliximab.

Infections
Tuberculosis, bacterial infections, including sepsis and pneumonia, invasive fungal infections, and other opportunistic infections have been observed in patients receiving REMICADE®. Some of these infections have been fatal. Opportunistic infections reported in patients on REMICADE® have included, but are not limited to pneumocystosis, histoplasmosis, cytomegalovirus infection, atypical mycobacterial infections, listeriosis and aspergillosis (see *Warnings and Precautions*)

In clinical studies 36% of infliximab-treated patients experienced infections compared with 25% of placebo-treated patients. No increased risk of serious infections was observed with REMICADE® compared with placebo in Crohn's disease studies and the Phase 3 study of psoriatic arthritis. In RA trials, the incidence of serious infections including pneumonia was higher in infliximab plus methotrexate treated patients compared with methotrexate alone especially at doses of 6mg/kg or greater (see *Warnings and Precautions*). In the psoriasis studies, 1.5% of patients (average of 41.9 weeks of follow-up) receiving REMICADE® and 0.6% of patients (average of 18.1 weeks of follow-up) receiving placebo developed serious infections.

In post-marketing spontaneous reporting, infections are the most common serious adverse event. Some of the cases have resulted in fatal outcome. Nearly 50% of reported deaths have been associated with infection. Cases of tuberculosis, sometimes fatal, including miliary tuberculosis and tuberculosis with extrapulmonary location have been reported (see *Warnings and Precautions*). In post-marketing experience, infections have been observed with various pathogens including viral, bacterial, fungal, and protozoal organisms. Infections have been noted in all organ systems and have been reported in patients receiving REMICADE® alone or in combination with immunosuppressive agents.

Malignancies and Lymphoproliferative Disorders
In clinical studies with infliximab in which 5706 patients were treated, representing 4990 patient years, 5 cases of lymphomas and 24 non-lymphoma malignancies were detected as compared with no lymphomas and 1 non-lymphoma malignancy in 1600 placebo-treated patients representing 892 patients years.

In long-term safety follow-up of clinical studies with infliximab of up to 5 years, representing 6234 patients-years (3210 patients), 5 cases of lymphoma and 38 cases of non-lymphoma malignancies were reported.

From August 1998 to August 2005, 1909 cases of suspected malignancies have been reported from post marketing, clinical trials and registries (321 in Crohn's disease patients, 1302 in rheumatoid arthritis patients and 286 in patients with other or unknown indications). Among those there were 347 lymphoma cases. During this period, the estimated exposure is 1,909, 941 patient years since first exposure (see *Warnings and Precautions - "Malignancies"*).

In an explanatory clinical trial involving patients with moderate to severe COPD who were either current smoker or ex-smokers, 157 patients were treated with REMICADE® at doses similar to those used in RA and Crohn's disease. Nine of these patients developed malignancies, including 1 lymphoma. The median duration of follow-up was 0.8 years (incidence 5.7% [95% CI 2.65%-10.6%]. There was one reported malignancy amongst 77 control patients (median duration of follow-up 0.8 years; incidence 1.3% [95% CI 0.03%- 7.0%]. The majority of the malignancies developed in the lung or head and neck.

Post-marketing cases of hepatosplenic T cell lymphoma have been reported in patients treated with REMICADE® with the vast majority of cases occurring in Crohn's disease and ulcerative colitis treated with REMICADE®, the majority and most of whom were adolescent or young adult males (see *Warnings and Precautions, Malignancies, Lymphoma*).

Heart Failure

In a phase 2 study aimed at evaluating REMICADE® in congestive heart failure (CHF), higher incidence of mortality due to worsening of heart failure were seen in patients treated with REMICADE®, especially those treated with the higher dose of 10 mg/kg (i.e. twice the maximum approved dose). In this trial 150 patients with NYHA Class III-IV CHF (left ventricular ejection fraction ≤35%) were treated with 3 infusions of REMICADE® 5 mg/kg, 10 mg/kg, or placebo over 6 weeks. At 38 weeks, 9 of 101 patients treated with REMICADE® (2 at 5 mg/kg and 7 at 10 mg/kg) died compared to one death among the 49 patients on placebo.

There have been post-marketing reports of worsening heart failure, with and without identifiable precipitating factors, in patients taking REMICADE®. There have also been post-marketing reports of new onset heart failure, including heart failure in patients without known pre-existing cardiovascular disease. Some of these patients have been under 50 years of age.

Antinuclear Antibodies (ANA)/Anti-Double-Stranded DNA (dsDNA) Antibodies

In clinical studies, approximately half of infliximab-treated patients who were ANA negative at baseline developed a positive ANA during the trial (compared with approximately one-fifth placebo-treated patients). Anti-dsDNA antibodies developed in approximately 17% of patients treated with infliximab (compared with 0% of placebo-treated patients). At the last evaluation, 57% infliximab-treated patients remained anti-dsDNA positive. Clinical signs consistent with a lupus-like syndrome remained uncommon.

Hepatobiliary Events

In clinical trials, mild or moderate elevations of ALT and AST have been observed in patients receiving REMICADE® without progression to severe hepatic injury. Elevations of ALT 5 x Upper Limit of Normal (ULN) have been observed (see Table 3). Elevations of aminotransferases were observed (ALT more common than AST) in a greater proportion of patients receiving REMICADE® than in controls, both when REMICADE® was given as monotherapy and when it was used in combination with other immunosuppressive agents. Most

aminotransferase abnormalities were transient; however, a small number of patients experienced more prolonged elevations. In general, patients who developed ALT and AST elevations were asymptomatic, and the abnormalities decreased or resolved with either continuation or discontinuation of REMICADE®, or modification of concomitant medications.

In post-marketing surveillance, cases of jaundice and hepatitis, some with features of autoimmune hepatitis, have been reported in patients receiving REMICADE® (see *Warnings and Precautions*).

Table 3: Proportion of patients with increased ALT activity in Clinical Trials

Indication	Number of patients [3]		Median follow-up (wks)[4]		Proportion of patients with increased ALT			
					≥3 x ULN		≥5 x ULN	
	placebo	infliximab	placebo	infliximab	placebo	infliximab	placebo	infliximab
Rheumatoid arthritis[1]	375	1087	58.1	58.3	3.2%	3.9%	0.8%	0.9%
Crohn's disease[2]	324	1034	53.7	54.0	2.2%	4.9%	0.0%	1.5%
Pediatric Crohn's disease	N/A	139	N/A	53.0	N/A	4.4%	N/A	1.5%
Ulcerative colitis	242	482	30.1	30.8	1.2%	2.5%	0.4%	0.6%
Pediatric Ulcerative colitis	N/A	60	N/A	49.4	N/A	6.7%	N/A	1.7%
Ankylosing spondylitis	76	275	24.1	101.9	0.0%	9.5%	0.0%	3.6%
Psoriatic arthritis	98	191	18.1	39.1	0.0%	6.8%	0.0%	2.1%
Plaque psoriasis	281	1175	16.1	50.1	0.4%	7.7%	0.0%	3.4%

[1]Placebo patients received methotrexate while infliximab patients received both infliximab and methotrexate.
[2]Placebo patients in the 2 of the 3 Phase 3 trials in Crohn's disease, ACCENT I and ACCENT II, received an initial dose of 5 mg/kg infliximab at study start and were on placebo in the maintenance phase. Patients who were randomized to the placebo maintenance group and then later crossed over to infliximab are included in the infliximab group in the ALT analysis. In the Phase 3b trial in Crohn's disease, SONIC, placebo patients received AZA 2.5 mg/kg/day in addition to placebo infusions.
[3]Number of patients evaluated for ALT.
[4] Median follow-up is based on patients treated.

Special Populations

Pediatrics

Pediatric Crohn's Disease Patients

The following adverse events were reported more commonly in pediatric Crohn's disease patients in the REACH trial (see section 5.1) than in adult Crohn's disease patients; anemia (10.7%), blood in stool (9.7%), leukopenia (8.7%), flushing (8.7%), viral infection (7.8%), neutropenia (6.8%), bone fracture (6.8%), bacterial infection (5.8%), and respiratory tract allergic reaction (5.8 %). Other special considerations are discussed below;

Infusion-Related Reactions

Overall, in REACH, 17.5% of randomised patients experienced 1 or more infusion reactions. There were no serious infusion reactions, and 2 subjects in REACH had non-serious anaphylactic reactions.

Immunogenicity
Antibodies to infliximab were detected in 3 (2.9%) pediatric patients.

Infections
In the REACH trial, infections were reported in 56.3% of randomised subjects treated with infliximab. Infections were reported more frequently for subjects who received q8 week as opposed to q12 week infusions (73.6% and 38.0%) respectively), while serious infections were reported for 3 subjects in the q8 week and 4 subjects in q12 week maintenance treatment group. The most commonly reported infections were upper respiratory tract infection and pharyngitis, and the most commonly reported serious infection was abscess. Three cases of pneumonia (1 serious) and 2 cases of herpes zoster (both non-serious) were reported.

Pediatric Ulcerative Colitis Patients
Overall proportions of patients with adverse events and serious adverse events were generally consistent in the pediatric ulcerative colitis and adult ulcerative colitis (ACT 1 and ACT 2) studies. In the pediatric ulcerative colitis study (Study Peds UC), the most common adverse event was worsening of ulcerative colitis which was greater in patients on the q12 week vs. the q8 week dosing regimen. In the ACT 1 and ACT 2 studies, the most common adverse event was headache. The most common serious adverse event across these three studies was worsening of the disease under study.

Infections were reported in 31 (51.7%) of 60 treated patients in Study Peds UC and 22 (36.7%) required oral or parenteral antimicrobial treatment. The proportion of patients with infections in Study Peds UC was similar to that in the pediatric Crohn's disease study (REACH) but higher than the proportion in the adults ulcerative colitis studies (ACT 1 and ACT 2). Unlike REACH, in which infections were reported more frequently for patients who received q8 week as opposed to q12 week infusions; in Study Peds UC, the overall incidence of infections was similar in the q8 week (13/22 [59.1%]) and q12 week (14/23 [60.9%]) maintenance treatment groups. In Study Peds UC, serious infections were reported for 3 of 22 (13.6%) patients in the q8 week and 3 of 23 (13.0%) patients in the q12 week maintenance treatment group. Upper respiratory tract infection (7/60 [11.7%]) and pharyngitis (5/60 [8.3%]) were the most frequently reported respiratory system infections among all treated patients. The infections occurring in more than one patient in a treatment group that required antimicrobial treatment were pharyngitis (4/60 [6.7%]), urinary tract infection (4/60 [6.7%]), and bronchitis (2/60 [3.3%]).

Overall, 8 (13.3%) of 60 treated patients experienced one or more infusion reactions, with 4 of 22 (18.2%) in the q8 week and 3 of 23 (13.0%) in the q12 week treatment maintenance group. No serious infusion reactions were reported. All infusion reactions were mild or moderate in intensity.

Antibodies to REMICADE® were detected in 4 (7.7%) patients through week 54.

In Study Peds UC, there were more patients in the 12 to 17 year age group than in the 6 to 11 year age group (45/60 [75.0%] vs.15/60 [25.0%]). While the numbers of patients in each subgroup are too small to make any definitive conclusions about the effect of age on safety events, there were higher proportions of patients with serious adverse events and discontinuation due to adverse events in the younger age group than in the older age group. While the proportion of patients with infections was also higher in the younger age group, for serious infections, the proportions were similar in the two age groups. Overall proportions of adverse events and infusion reactions were similar between the 6 to 11 and 12 to 17 year age groups.

Post-Marketing Experience
Post-marketing spontaneous serious adverse events with infliximab in the paediatric population have included malignancies including hepatosplenic T-cell lymphomas, transient hepatic enzyme abnormalities, lupus-like syndrome, and positive autoantibodies (see *Warnings and Precautions, and Adverse Reactions, Malignancies and Lymphoproliferative Disorders*).

Overdose
Single doses up to 20 mg/kg have been administered without toxic effects. There is no clinical experience of overdose.

PHARMACOLOGICAL PROPERTIES
Pharmacodynamic Properties
Pharmacotherapeutic group: Tumor necrosis factor alpha (TNFα) inhibitors
ATC code: L04AB02.

Pharmacodynamic Properties
Infliximab is a chimeric human-murine monoclonal antibody that binds with high affinity to both soluble and transmembrane forms of TNFα but not to lymphotoxin α (TNFß). Infliximab inhibits the functional activity of TNFα in a wide variety of *in vitro* bioassays. Infliximab prevented disease in transgenic mice that develop polyarthritis as a result of constitutive expression of human TNFα and when administered after disease onset, it allowed eroded joints to heal. *In vivo*, infliximab rapidly forms stable complexes with human TNFα, a process that parallels the loss of TNFα bioactivity.

Elevated concentrations of TNFα have been found in the joints of rheumatoid arthritis patients and correlate with elevated disease activity. In rheumatoid arthritis, treatment with infliximab reduced infiltration of inflammatory cells into inflamed areas of the joint as well as expression of molecules mediating cellular adhesion, chemoattraction and tissue degradation. After infliximab treatment, patients exhibited decreased levels of serum interleukin 6 (IL-6) and C-reactive protein (CRP) compared with baseline. Peripheral blood lymphocytes further showed no significant decrease in number or in proliferative responses to *in vitro* mitogenic stimulation when compared with untreated patients' cells. In psoriasis patients, treatment with infliximab resulted in decreases in epidermal inflammation and normalization of keratinocyte differentiation in psoriatic plaques. In psoriatic arthritis, short term treatment with REMICADE® reduced the number of T-cells and blood vessels in the synovium and psoriatic skin.

Histological evaluation of colonic biopsies, obtained before and 4 weeks after administration of infliximab, revealed a substantial reduction in detectable TNFα. Infliximab treatment of Crohn's disease patients was also associated with a substantial reduction of the commonly elevated serum inflammatory marker, CRP. Total peripheral white blood cell counts were minimally affected in infliximab-treated patients, although changes in lymphocytes, monocytes and neutrophils reflected shifts towards normal ranges. Peripheral blood mononuclear cells (PBMC) from infliximab-treated patients showed undiminished proliferative responsiveness to stimuli compared with untreated patients, and no substantial changes in cytokine production by stimulated PBMC were observed following treatment with infliximab. Analysis of lamina propria mononuclear cells obtained by biopsy of the intestinal mucosa showed that infliximab treatment caused a reduction in the number of cells capable of expressing TNFα and interferonγ. Additional histological studies provided evidence that treatment with infliximab

reduces the infiltration of inflammatory cells into affected areas of the intestine and the presence of inflammation markers at these sites.

Clinical Efficacy

Rheumatoid Arthritis

The efficacy of infliximab was assessed in two multicentre, randomised, double-blind, pivotal trials: ATTRACT and ASPIRE. In both studies concurrent use of stable doses of folic acid, oral corticosteroids (≤ 10 mg/day) and/or non-steroidal anti-inflammatory drugs were permitted.

The primary endpoints were the reduction of signs and symptoms as assessed by the American College of Rheumatology criteria (ACR20 for ATTRACT, landmark ACR-N for ASPIRE), the prevention of structural joint damage, and the improvement in physical function. A reduction in signs and symptoms was defined to be at least a 20% improvement (ACR20) in both tender and swollen joint counts, and in 3 of the following 5 criteria: (1) evaluator's global assessment, (2) patient's global assessment, (3) functional/disability measure, (4) visual analog pain scale and (5) erythrocyte sedimentation rate or C-reactive protein. ACR-N uses the same criteria as the ACR20, calculated by taking the lowest percent improvement in swollen joint count, tender joint count, and the median of the remaining 5 components of the ACR response. Structural joint damage (erosions and joint space narrowing) in both hands and feet was measured by the change from baseline in the total van der Heijde-modified Sharp score (0-440). The Health Assessment Questionnaire (HAQ; scale 0-3) was used to measure patients' average change from baseline scores over time, in physical function.

The ATTRACT trial evaluated responses at 30, 54 and 102 weeks in a placebo-controlled study of 428 patients with active rheumatoid arthritis despite treatment with methotrexate. Approximately 50% of patients were in functional Class III. Patients received placebo, 3 mg/kg or 10 mg/kg infliximab at weeks 0, 2 and 6, and then every 4 or 8 weeks thereafter. All patients were on stable methotrexate doses (median 15 mg/wk) for 6 months prior to enrolment and were to remain on stable doses throughout the study.

Results from week 54 (ACR20, HAQ and total van der Heijde-modified Sharp score) are shown in Table 4. Higher degrees of clinical response (ACR50 and ACR70) were observed in all infliximab groups at 30 and 54 weeks compared with methotrexate alone.

A reduction in the rate of the progression of structural joint damage (erosions and joint space narrowing) was observed in all infliximab groups at 54 weeks (Table 4).

The effects observed at 54 weeks were maintained through 102 weeks. Due to a number of treatment withdrawals, the magnitude of the effect difference between infliximab and the methotrexate alone group cannot be defined.

Table 4: Effects on ACR20, Structural Joint Damage and Physical Function at week 54

		infliximab[b]				
	Control[a]	3 mg/kg q 8 wks	3 mg/kg q 4 wks	10 mg/kg q 8 wks	10 mg/kg q 4 wks	All infliximab[b]
Patients with ACR20 response/ patients evaluated (%)[c]	15/88 (17%)	36/86 (42%)	41/86 (48%)	51/87 (59%)	48/81 (59%)	176/340 (52%)
Total score[d] (van der Heijde-modified Sharp score)						
Change from baseline (Mean ± SD[c])	7.0 ± 10.3	1.3 ± 6.0	1.6 ± 8.5	0.2 ± 3.6	-0.7 ± 3.8	0.6 ± 5.9

Median[c] (Interquartile range)	4.0 (0.5,9.7)	0.5 (-1.5,3.0)	0.1 (-2.5,3.0)	0.5 (-1.5,2.0)	-0.5 (-3.0,1.5)	0.0 (-1.8,2.0)
Patients with no deterioration/patients evaluated (%)[c]	13/64 (20%)	34/71 (48%)	35/71 (49%)	37/77 (48%)	44/66 (67%)	150/285 (53%)
HAQ change from baseline over time[e] (patients evaluated)	87	86	85	87	81	339
Mean ± SD[c]	0.2 ± 0.3	0.4 ± 0.3	0.5 ± 0.4	0.5 ± 0.5	0.4 ± 0.4	0.4 ± 0.4

a: control = All patients had active RA despite treatment with stable methotrexate doses for 6 months prior to enrolment and were to remain on stable doses throughout the study. Concurrent use of stable doses of oral corticosteroids (≤ 10 mg/day) and/or non-steroidal anti-inflammatory drugs was permitted, and folate supplementation was given.
b: all infliximab doses given in combination with methotrexate and folate with some on corticosteroids and/or non-steroidal anti-inflammatory drugs
c: $p < 0.001$, for each infliximab treatment group vs. control
d: greater values indicate more joint damage.
e: HAQ = Health Assessment Questionnaire; greater values indicate less disability.

The ASPIRE trial evaluated responses at 54 weeks in 1004 methotrexate naïve patients with early (≤3 years disease duration, median 0.6 years) active rheumatoid arthritis (median swollen and tender joint count of 19 and 31, respectively). All patients received methotrexate (optimised to 20 mg/wk by week 8) and either placebo, 3 mg/kg or 6 mg/kg infliximab at weeks 0, 2, and 6 and every 8 weeks thereafter. Results from week 54 are shown in Table 5.

After 54 weeks of treatment, both doses of infliximab + methotrexate resulted in statistically significantly greater improvement in signs and symptoms compared to methotrexate alone as measured by the proportion of patients achieving ACR20, 50 and 70 responses.

In ASPIRE, more than 90% of patients had at least two evaluable X-rays. Reduction in the rate of progression of structure damage was observed at weeks 30 and 54 in the infliximab + methotrexate groups compared to methotrexate alone.

Table 5: Effects on ACRn, Structural Joint Damage and Physical Function at week 54, ASPIRE

		Infliximab + MTX		
	Placebo + MTX	3 mg/kg	6 mg/kg	Combined
Subjects randomised	282	359	363	722
Percentage ACR improvement				
Mean ± SD[a]	24.8 ± 59.7	37.3 ± 52.8	42.0 ± 47.3	39.6 ± 50.1
Change from baseline in total van der Heijde modified Sharp score[b]				
Mean ± SD[a]	3.70 ± 9.61	0.42 ± 5.82	0.51 ± 5.55	0.46 ± 5.68
Median	0.43	0.00	0.00	0.00
Improvement from baseline in HAQ averaged over time from week 30 to week 54[c]				
Mean ± SD[d]	0.68 ± 0.63	0.80 ± 0.65	0.88 ± 0.65	0.84 ± 0.65

a: $p < 0.001$, for each infliximab treatment group vs. control
b: greater values indicate more joint damage.
c: HAQ = Health Assessment Questionnaire; greater values indicate less disability.
d: $p = 0.030$ and < 0.001 for the 3mg/kg and 6mg/kg treatment groups respectively vs. placebo + MTX.

Adult Crohn's Disease

Induction Treatment in Moderately to Severely Active Crohn's Disease

The efficacy of a single dose treatment with infliximab was assessed in 108 patients with active Crohn's disease (Crohn's Disease Activity Index (CDAI) ≥ 220 ≤ 400) in a randomised, double-blinded, placebo-controlled, dose-response study. Of these 108 patients, 27 were treated

with the recommended dosage of infliximab 5 mg/kg. All patients had experienced an inadequate response to prior conventional therapies. Concurrent use of stable doses of conventional therapies was permitted, and 92% of patients continued to receive these medications.

The primary endpoint was the proportion of patients who experienced a clinical response, defined as a decrease in CDAI by ≥ 70 points from baseline at the 4-week evaluation and without an increase in Crohn's disease medications or surgery for Crohn's disease. Patients who responded at week 4 were followed to week 12. Secondary endpoints included the proportion of patients in clinical remission at week 4 (CDAI < 150) and clinical response over time.

At week 4, following a single dose of study medication, 22/27 (81%) of infliximab-treated patients receiving a 5 mg/kg dose achieved a clinical response vs. 4/25 (16%) of the placebo-treated patients ($p < 0.001$). Also at week 4, 13/27 (48%) of infliximab-treated patients achieved a clinical remission (CDAI < 150) vs. 1/25 (4%) of placebo-treated patients. A response was observed within 2 weeks, with a maximum response at 4 weeks. At the last observation at 12 weeks, 13/27 (48%) of infliximab-treated patients were still responding.

Maintenance Treatment in Moderately to Severely Active Crohn's Disease
The efficacy of repeated infusions with infliximab was studied in a 1-year clinical study.
A total of 573 patients with active Crohn's disease (DCAI ≥ 220 ≤ 400) received a single infusion of 5 mg/kg at week 0. Sixty-eight of these patients (12%) belonged to the population defined in the indication (see *Indications*). Three hundred and thirty-five patients (58%) responding to the 5 mg/kg infusion at week 2 were randomised to one of three treatment groups; a placebo maintenance group, 5 mg/kg maintenance group and 10 mg/kg maintenance group, receiving repeated infusions at week 2, 6 and every eight weeks.

At week 30, a significantly greater proportion of patients in the combined infliximab maintenance treatment group (42%) achieved clinical remission, compared with patients in the placebo maintenance group (21%). Median time to loss of response was 46 weeks in the combined infliximab maintenance treatment group vs. 19 weeks in the placebo maintenance group ($p<0.001$). Similar results were obtained in the subgroup analyses of the population defined in the indication (see *Indications*).

Improvements in quality of life measures were seen for both the IBDQ and SF-36 scores in the infliximab maintenance groups compared with the placebo maintenance group at week 30 ($p<0.001$).

Infliximab with or without AZA was assessed in a randomized, double-blind, active comparator study (SONIC) of 508 adult patients with moderate to severe Crohn's disease (CDAI ≥ 220 ≤ 450) who were naive to biologics and immunosuppressants and had a median disease duration of 2.3 years. At baseline 27.4% of patients were receiving systemic corticosteroids, 14.2% of patients were receiving budesonide, and 54.3% of patients were receiving 5-ASA compounds. Patients were randomized to receive AZA monotherapy, infliximab monotherapy, or infliximab plus AZA combination therapy. Infliximab was administered at a dose of 5 mg/kg at weeks 0, 2, 6, and then every 8 weeks. AZA was given at a dose of 2.5 mg/kg daily.

The primary endpoint of the study was corticosteroid-free clinical remission at Week 26, defined as patients in clinical remission (CDAI of <150) who, for at least 3 weeks, had not taken oral systemic corticosteroids (prednisone or equivalent) or budesonide at a dose > 6

mg/day. For results see Table 6. The proportions of patients with mucosal healing at Week 26 were significantly greater in the infliximab plus AZA combination (43.9%, p<0.001) and infliximab monotherapy groups (30.1%, p=0.023) compared to the AZA monotherapy group (16.5%).

Table 6: Percent of patients achieving corticosteroid-free clinical remission at Week 26, SONIC

	AZA Monotherapy	Infliximab Monotherapy	Infliximab + AZA Combination Therapy
Week 26			
All randomized patients	30.0% (51/170)	44.4% (75/169) (p=0.006)*	56.8% (96/169) (p<0.001)*

* P-values represent each infliximab treatment group vs. AZA monotherapy

Similar trends in the achievement of corticosteroid-free clinical remission were observed at Week 50. Furthermore, improved quality of life as measured by IBDQ was observed with infliximab.

Induction Treatment in Fistulising Active Crohn's Disease

The efficacy was assessed in a randomised, double-blinded, placebo-controlled study in 94 patients with fistulising Crohn's disease who had fistulae that were of at least 3 months' duration. Thirty-one of these patients were treated with infliximab 5 mg/kg. Approximately 93% of the patients had previously received antibiotic or immunosuppressive therapy.

Concurrent use of stable doses of conventional therapies was permitted, and 83% of patients continued to receive at least one of these medications. Patients received three doses of either placebo or infliximab at weeks 0, 2 and 6. Patients were followed up to 26 weeks. The primary endpoint was the proportion of patients who experienced a clinical response, defined as ≥ 50% reduction from baseline in the number of fistulae draining upon gentle compression on at least two consecutive visits (4 weeks apart), without an increase in medication for Crohn's disease.

Sixty-eight percent (21/31) of infliximab-treated patients receiving a 5 mg/kg dose regimen achieved a clinical response vs. 26% (8/31) placebo-treated patients (p = 0.002). The median time to onset of response in the infliximab-treated group was 2 weeks. The median duration of response was 12 weeks. Additionally, closure of all fistulae was achieved in 55% of infliximab-treated patients compared with 13% of placebo-treated patients (p = 0.001).

Maintenance Treatment in Fistulising Active Crohn's Disease

The efficacy of repeated infusions with infliximab in patients with fistulising Crohn's disease was studied in a 1-year clinical study. A total of 306 patients received 3 doses of infliximab 5 mg/kg at week 0, 2 and 6. At baseline, 87% of the patients had perianal fistulae, 14% had abdominal fistulae, 9% had rectovaginal fistulae. The median CDAI score was 180. At week 14, 282 patients were assessed for clinical response and randomised to receive either placebo or 5 mg/kg infliximab every 8 weeks through week 46.

Week-14 responders (195/282) were analyzed for the primary endpoint, which was time from randomisation to loss of response (see Table 7). Corticosteroid tapering was permitted after week 6.

Table 7: Effects on response rate, data from ACCENT II (Week-14 responders)

	ACCENT II (Week-14 responders)		
	Placebo Maintenance (n=99)	Infliximab Maintenance (5 mg/kg) (n=96)	p-value

Median time to loss of response through week 54	14 weeks	>40 weeks	< 0.001
Week 54			
Fistula Response (%) [a]	23.5	46.2	0.001
Complete fistula response (%) [b]	19.4	36.3	0.009

a: A ≥50% reduction from baseline in the number of draining fistulas over a period of ≥4 weeks
b: Absence of any draining fistulas

Beginning at week 22, patients who initially responded to treatment and subsequently lost their response were eligible to cross over to active re-treatment every 8 weeks at a dose of infliximab 5 mg/kg higher than the dose to which they were originally randomised. Among patients in the infliximab 5 mg/kg group who crossed over because of loss of fistula response after week 22, 57% (12/21) responded to re-treatment with infliximab 10 mg/kg every 8 weeks.

There was no significant difference between placebo and infliximab for the proportion of patients with sustained closure of all fistulas through week 54, for symptoms such as proctalgia, abscesses and urinary tract infection or for number of newly developed fistulas during treatment.

Maintenance therapy with infliximab every 8 weeks significantly reduced disease-related hospitalisations and surgeries compared with placebo. Furthermore, a reduction in corticosteroid use and improvements in quality of life were observed.

Pediatric Crohn's Disease (6 to 17 years)

In the REACH trial, 112 patients (6 to 17 years, median age 13.0 years) with moderate to severe, active Crohn's disease (median PCDAI of 40) and an inadequate response to conventional therapies were to receive 5mg/kg infliximab at weeks 0, 2, and 6. All patients were required to be on a stable dose of 6-mercaptopurine (6-MP), azathioprine (AZA) or methotrexate (MTX) (35% were also receiving corticosteroids at baseline). Patients assessed by the investigator to be in clinical response at week 10 were randomised and received 5mg/kg infliximab either q8 weeks or q12 weeks as maintenance treatment regimen. If response was lost during treatment, crossing over to a higher dose (10mg/kg) and/or shorter dosing interval (q8 weeks) was allowed. Thirty-two (32) evaluable paediatric patients crossed over (9 subjects in the q8 weeks and 23 subjects in the q12 weeks maintenance groups). Twenty four of these patients (75.0%) regained clinical response after crossing over.

The proportion of subjects in clinical response at week 10 was 88.4% (99/112). The proportion of subjects achieving clinical remission at week 10 was 58.9% (66/112).

At week 30, the proportion of subjects in clinical remission was higher in the q8 week (59.6%, 31/52) than the q12 week maintenance treatment group (35.3%, 18/51; p=0.013) at week 54, the figures were 55.8% (29/52) and 23.5% (12/51) in the q8 weeks and q12 weeks maintenance groups, respectively (p<0.001).

Data about fistulas were derived from PCDAI scores. Of the 22 subjects that had fistulas at baseline, 63.6% (14/22), 59.1% (13/22) and 68.2% (15/22) were in complete fistula response at week 10, 30 and 54, respectively, in the combined q8 weeks and q12 weeks maintenance groups.

In addition, statistically and clinically significant improvements in quality of life and height, as well as a significant reduction in corticosteroid use, were observed versus baseline.

Ulcerative Colitis

The safety and efficacy of REMICADE® were assessed in two (ACT 1 and ACT 2) randomised, double-blind, placebo-controlled clinical studies in adult patients with moderately to severely active ulcerative colitis (Mayo score 6 to 12; Endoscopy subscore ≥ 2) with an inadequate response to conventional therapies [oral corticosteroids, aminosalicylates and/or immunomodulators (6-MP, AZA)]. Concomitant stable doses of oral aminosalicylates, corticosteroids, and/or immunomodulatory agents were permitted. In both studies, patients were randomized to receive either placebo, 5 mg/kg REMICADE®, or 10 mg/kg REMICADE® at weeks 0, 2, 6, 14 and 22, and in ACT 1 at weeks 30, 38 and 46. Corticosteroid taper was permitted after week 8.

Table 8: Effects on clinical response, clinical remission and mucosal healing at Weeks 8 and 30. Combined data from ACT1 & 2.

		Infliximab		
	Placebo	5 mg/kg	10 mg/kg	Combined
Subjects randomized	244	242	242	484
Percentage of subjects in clinical response and in sustained clinical response				
Clinical response at Week 8[a]	33.2%	66.9%	65.3%	66.1%
Clinical response at Week 30[a]	27.9%	49.6%	55.4%	52.5%
Sustained response (clinical response at both Week 8 and Week 30)[a]	19.3%	45.0%	49.6%	47.3%
Percentage of subjects in clinical remission and sustained remission				
Clinical remission at Week 8[a]	10.2%	36.4%	29.8%	33.1%
Clinical remission at Week 30[a]	13.1%	29.8%	36.4%	33.1%
Sustained remission (in remission at both Week 8 and Week 30)[a]	5.3%	19.0%	24.4%	21.7%
Percentage of subjects with mucosal healing				
Mucosal healing at Week 8[a]	32.4%	61.2%	60.3%	60.7%
Mucosal healing at Week 30[a]	27.5%	48.3%	52.9%	50.6%

a: $p < 0.001$, for each infliximab treatment group vs. placebo

The efficacy of REMICADE® through week 54 was assessed in the ACT 1 trial.

At 54 weeks, 44.9% of patients in the combined infliximab treatment group were in clinical response compared to 19.8% in the placebo treatment group ($p<0.001$). Clinical remission and mucosal healing occurred in greater proportion of patients in the combined infliximab treatment group compared to the placebo treatment group at week 54 (34.5% vs. 16.5%, $p<0.001$ and 46.1% vs. 18.2%, $p<0.001$, respectively). The proportions of patients in sustained response and sustained remission at week 54 were greater in the combined infliximab treatment group than in placebo treatment group (37.9% vs. 14.0%, $p<0.001$; and 20.2% vs. 6.6%, $p<0.001$, respectively).

Infliximab improved Quality of Life, confirmed by statistically and clinically significant improvement in both disease specific measure, IBDQ, and by improvement in the generic 36-item short form survey SF-36.

From baseline through week 30 in the pooled data from ACT 1 and ACT 2, the mean number of hospitalizations was 50% lower in the combined infliximab treatment group than in the placebo treatment group (9 versus 18 hospitalizations per 100 subjects, $p = 0.005$). No notable differences were observed between the 5 mg/kg and 10 mg/kg infliximab treatment groups.

A greater proportion of patients in the combined infliximab treatment group were able to discontinue corticosteroids in clinical remission compared to the placebo treatment group at both week 30 (22.3% versus 7.2%, $p \leq 0.001$) and week 54 (21.0% vs. 8.9%, p=0.022).

Ulcerative Colitis in Pediatric Patients

The safety and efficacy of REMICADE® were assessed in a multi-center, randomized, open-label, parallel-group Phase 3 clinical study in 60 pediatric patients aged 6 through 17 years (median age 14.5 years) with moderately to severely active ulcerative colitis (Mayo score of 6 to 12; Endoscopic subscore ≥ 2) with an inadequate response to conventional therapies (Study Peds UC). At baseline 53% of patients were receiving immunomodulator therapy (6-mercaptopurine (6-MP)/ azathioprine (AZA)/ methotrexate (MTX)) and 62% of patients were receiving corticosteroids. Discontinuation of immunomodulators and corticosteroid taper were permitted after Week 0.

All patients received an induction regimen of 5 mg/kg infliximab at Weeks 0, 2, and 6. Patients (15) who did not respond to REMICADE® at Week 8 received no further drug and returned for safety follow-up. At Week 8, 45 patients were randomized in a 1:1 ratio to one of two maintenance treatment regimens: 5 mg/kg infliximab every 8 weeks (q8 week) through Week 46 or every 12 weeks (q12 week) through Week 42.

The primary endpoint was clinical response at Week 8, defined as a decrease from baseline in the Mayo score by ≥ 30% and ≥ 3 points, with a decrease in the rectal bleeding subscore of ≥ 1 or a rectal bleeding subscore of 0 or 1.

Major secondary endpoints included clinical remission measured by the Mayo score at Week 8, remission by the Pediatric Ulcerative Colitis Activity Index (PUCAI)[31] score at Week 8 and Week 54, and mucosal healing at Week 8. For patients receiving corticosteroids at baseline, reduction in median corticosteroid use, and remission combined with elimination of corticosteroid use at Week 54 was evaluated.

Clinical Response, Clinical Remission and Mucosal Healing

Of the 60 patients treated, 44 (73.3%) were in clinical response at Week 8 (95% CI: 62.1%, 84.5%). The proportions of patients achieving clinical response at Week 8 were similar between those taking concomitant immunomodulators at baseline (72%) and those not taking concomitant immunomodulators at baseline (75%).

Clinical remission was defined by a Mayo score of ≤ 2 points, with no individual subscore > 1. Remission was also defined by a PUCAI score of <10 points. At Week 8, infliximab induced clinical remission in 40% (24/60) of patients as measured by the Mayo score and in 33.3% (17/51) of patients as measured by the PUCAI score.

The proportion of patients in remission at Week 54 as measured by the PUCAI score was 38% (8/21) in the q8 week maintenance treatment group and 18% (4/22) in the q12 week maintenance treatment group.

Mucosal healing was defined as an endoscopy subscore (from the Mayo score) of 0 or 1. At Week 8, 68.3% (41/60) of patients were in mucosal healing with 33.3% (20/60) having an endoscopy subscore of 0 (indicating normal or inactive disease). Of the 9 patients who had an optional endoscopy at Week 54, 8 were in mucosal healing.

Overall, although some differences were noted between the age groups in the efficacy measures examined, efficacy was observed in both age groups and no consistent pattern indicating greater

efficacy in one of the age groups was apparent. The differences between the 6 to 11 and the 12 to 17 year old age groups, however, are difficult to assess because of the small sample sizes, particularly in the 6 to 11 year old age group (15 patients).

Corticosteroid use and Remission

Median average daily corticosteroid (prednisone equivalent) dose (mg/kg/day) through Week 54 is presented in Figure 1 for all randomized patients taking corticosteroids at baseline (14 patients in each maintenance treatment group).




Figure 1: Line plot of median average daily corticosteroid (prednisone equivalent) dose (mg/kg/day) through Week 54; randomized patients taking corticosteroids at baseline

At week 54, the proportion of patients in clinical remission as measured by the PUCAI score was 38% (8/21) in the q8 week maintenance group and 18% (4/22) in the q12 week maintenance treatment group. For patients receiving corticosteroids at baseline, the proportion of patients in remission and not receiving corticosteroids at week 54 was 38.5% (5/13) for the q8 week and 0% (0/13) for the q12 week maintenance treatment group.

For patients receiving corticosteroids at baseline in Study Peds UC, the proportion of these patients in remission and not receiving corticosteroids at Week 54 was 38.5% (5 of 13) for the q8 week and 0% (0 of 13) for the q12 week maintenance treatment group.

Ankylosing Spondylitis

Efficacy and safety were studied in a double-blind, placebo-controlled investigator initiated, multicenter study evaluating infliximab in 70 patients with active ankylosing spondylitis (disease activity [Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score > 4] and pain [NRS score > 4]). During the 3-month double-blind phase, patients received either 5 mg/kg infliximab or placebo at weeks 0, 2, 6 (35 patients in each group). Starting at week 12, placebo patients were switched to infliximab and all patients subsequently received 5 mg/kg infliximab every 6 weeks up to week 54.

Treatment with infliximab resulted in improvement in signs and symptoms, as assessed by the BASDAI, with 57% of infliximab treated patients achieving at least 50% reduction from

baseline in BASDAI score (mean baseline score was 6.5 in the infliximab group and 6.3 in the placebo group, compared with 9% of placebo patients ($p<0.01$). Improvement was observed at week 2 and was maintained through week 54. Physical function and quality of life (SF36) were improved similarly. In the trial, efficacy was not shown in HLA-B27 negative patients (n=7).

Psoriatic Arthritis

Efficacy and safety were studied in a double-blind, placebo-controlled, multicenter study evaluating infliximab in 104 patients with active polyarticular psoriatic arthritis. In total 74 subjects were on at least one concomitant DMRD, and among those 58 patients were treated with methotrexate. During the 16-week double-blind phase, patients received either 5 mg/kg infliximab or placebo at weeks 0, 2, 6, and 14 (52 patients in each group). Starting at week 16, placebo patients were switched to infliximab and all patients subsequently received 5 mg/kg infliximab every 8 weeks up to week 46. After the first year of the study, 78 patients continued into an open-label extension to week 98.

In the second trial (IMPACT 2), efficacy and safety of infliximab were studied in 200 patients with active psoriatic arthritis (≥ 5 swollen joints and ≥ 5 tender joints). Forty-six percent of patients continued on stable doses of methotrexate (≤25 mg/week). During the 24-week double-blind phase, patients received either 5 mg/kg infliximab or placebo at weeks 0, 2, 6, 14, and 22 (100 patients in each group). At week 16, 47 placebo patients with < 10% improvement from baseline in both swollen and tender joint counts were switched to infliximab induction (early escape). At week 24, all placebo treated patients crossed over to infliximab induction. Dosing continued for all patients through week 46.

Key efficacy results for IMPACT and IMPACT 2 are shown in table 9 below:

Table 9: Effects on ACR and PASI in IMPACT and IMPACT 2

	IMPACT			IMPACT 2*		
	Placebo (Week 16)	Infliximab (Week 16)	Infliximab (Week 98)	Placebo (Week 24)	Infliximab (Week 24)	Infliximab (Week 54)
Patients randomized	52	52	N/A[a]	100	100	100
ACR response (% of patients)						
N	52	52	78	100	100	100
ACR 20 response*	5(10%)	34 (65%)	48 (62%)	16 (16%)	54 (54%)	53 (53%)
ACR 50 response*	0(0%)	24 (46%)	35 (45%)	4 (4%)	41(41%)	33 (33%)
ACR 70 response*	0(0%)	15 (29%)	27 (35%)	2 (2%)	27 (27%)	20 (20%)
PASI response (% of patients)[b]						
N				87	83	82
PASI 75 response**				1 (1%)	50 (60%)	40 (48.8%)

* ITT-analysis where subjects with missing data were included as non-responders

[a]Week 98 data for IMPACT includes combined placebo crossover and infliximab patients who entered the open-label extension

[b]Based on patients with PASI >2.5 at baseline for IMPACT, and patients with >3% BSA psoriasis skin involvement at baseline in IMPACT 2

** PASI 75 response for IMPACT not included due to low N; $p<0.001$ for infliximab vs. placebo at week 24 for IMPACT 2

In IMPACT and IMPACT 2, clinical responses were observed as early as week 2 and were maintained through week 98 and week 54 respectively. Efficacy has been demonstrated with or without concomitant use of methotrexate. Decreases in parameters of peripheral activity characteristic of psoriatic arthritis (such as number of swollen joints, number of painful/tender joints, dactylitis and presence of enthesopathy) were seen in the infliximab-treated patients.

Infliximab-treated patients demonstrated significant improvement in physical function as assessed by HAQ. Significant improvements in health-related quality of life were also demonstrated as measured by the physical and mental component summary scores of the SF-36 in IMPACT 2.

Psoriasis

The efficacy of infliximab was assessed in two multicenter, randomised, double blind studies: SPIRIT and EXPRESS. Patients in both studies had plaque psoriasis (Body Surface Area [BSA] ≥10% and Psoriasis Area and Severity Index [PASI] score ≥12). The primary endpoint in both studies was the percent of patients who achieved ≥ 75% improvement in PASI from baseline at week 10.

SPIRIT evaluated the efficacy of infliximab induction therapy in 249 patients with plaque psoriasis that had previously received PUVA or systemic therapy. Patients received either 3 or, 5 mg/kg infliximab or placebo infusions at weeks 0, 2 and 6. Patients with a PGA score ≥3 were eligible to receive an additional infusion of the same treatment at week 26.

In SPIRIT, the proportion of patients achieving PASI 75 at week 10 was 71.7% in the 3 mg/kg infliximab group, 87.9% in the 5 mg/kg infliximab group, and 5.9% in the placebo group ($p < 0.001$).

By week 26, twenty weeks after the last induction dose, 30% of patients in the 5mg/kg group and 13.8% of patients in the 3mg/kg group were PASI 75 responders. Between weeks 6 and 26, symptoms of psoriasis gradually returned with a median time to disease relapse of > 20 weeks. No rebound was observed.

EXPRESS evaluated the efficacy of infliximab induction and maintenance therapy in 378 patients with plaque psoriasis. Patients received 5 mg/kg infliximab or placebo infusions at weeks 0, 2 and 6 followed by maintenance therapy every 8 weeks through week 22 in the placebo group and through week 46 in the infliximab group. At week 24, the placebo group crossed over to infliximab induction therapy (5 mg/kg) followed by infliximab maintenance therapy (5 mg/kg). Nail psoriasis was assessed using the Nail Psoriasis Severity Index (NAPSI). Prior therapy with PUVA, methotrexate, cyclosporin, or acitretin had been received by 71.4% of patients, although they were not necessarily therapy resistant. Key results are presented in Table 10. In infliximab treated subjects, significant PASI 50 responses were apparent at the first visit (week 2) and PASI 75 responses by the second visit (week 6). Efficacy was similar in the subgroup of patients that were exposed to previous systemic therapies compared to the overall study population.

Table 10: Summary of PASI response, PGA response and percent of patients with all nails cleared at Weeks 10, 24 and 50. EXPRESS

	Placebo → Infliximab 5 mg/kg (at week 24)	Infliximab 5 mg/kg
Week 10		
n	77	301
≥ 90% improvement	1 (1.3%)	172 (57.1%)[a]

≥ 75% improvement	2 (2.6%)	242 (80.4%)[a]
≥ 50% improvement	6 (7.8%)	274 (91.0%)
PGA of cleared (0) or minimal (1)	3 (3.9%)	242 (82.9%) [ab]
PGA of cleared (0), minimal (1), or mild (2)	14 (18.2%)	275 (94.2%)[ab]
Week 24		
n	77	276
≥ 90% improvement	1 (1.3%)	161 (58.3%)[a]
≥ 75% improvement	3 (3.9%)	227 (82.2%)[a]
≥ 50% improvement	5 (6.5%)	248 (89.9%)
PGA of cleared (0) or minimal (1)	2 (2.6%)	203 (73.6%)[a]
PGA of cleared (0), minimal (1), or mild (2)	15 (19.5%)	246 (89.1%)[a]
Week 50		
n	68	281
≥ 90% improvement	34 (50.0%)	127 (45.2%)
≥ 75% improvement	52 (76.5%)	170 (60.5%)
≥ 50% improvement	61 (89.7%)	193 (68.7%)
PGA of cleared (0) or minimal (1)	46 (67.6%)	149 (53.0%)
PGA of cleared (0), minimal (1), or mild (2)	59 (86.8%)	189 (67.3%)
All nails cleared [c]		
Week 10	1/65(1.5%)	16/235 (6.8%)
Week 24	3/65 (4.6%)	58/223 (26,0%) [a]
Week 50	27/64 (42.2%)	92/226 (40.7%)

a: p<0.001, for each infliximab treatment group vs. control
b: n = 292
c: Analysis was based on subjects with nail psoriasis at baseline (81.8% of subjects). Mean baseline NAPSI scores were 4.6 and 4.3 in infliximab and placebo group.

Significant improvements from baseline were demonstrated in DLQI (p<0.001) and the physical and mental component scores of the SF 36 (p<0.001 for each component comparison).

Pharmacokinetic Properties

Adults

Single intravenous infusions of 1, 3, 5, 10 or 20 mg/kg of infliximab yielded dose proportional increases in the maximum serum concentration (C_{max}) and area under the concentration-time curve (AUC). The volume of distribution at steady state (median V_d of 3.0 to 4.1 litres) was not dependent on the administered dose and indicated that infliximab is predominantly distributed within the vascular compartment. No time-dependency of the pharmacokinetics was observed. The elimination pathways for infliximab have not been characterised. Unchanged infliximab was not detected in urine. No major age- or weight-related differences in clearance or volume of distribution were observed in rheumatoid arthritis patients. The pharmacokinetics of infliximab in elderly patients has not been studied. Studies have not been performed in patients with liver or renal disease.

At single doses of 3, 5, or 10 mg/kg, the median C_{max} values were 77, 118 and 277 micrograms/ml, respectively. The median terminal half-life at these doses ranged from 8 to 9.5 days. In most patients, infliximab could be detected in the serum for at least 8 weeks after the recommended single dose of 5 mg/kg for Crohn's disease and the rheumatoid arthritis maintenance dose of 3 mg/kg every 8 weeks.

Repeated administration of infliximab (5 mg/kg at 0, 2 and 6 weeks in fistulising Crohn's disease, 3 or 10 mg/kg every 4 or 8 weeks in rheumatoid arthritis) resulted in a slight accumulation of infliximab in serum after the second dose. No further clinically relevant accumulation was observed. In most fistulising Crohn's disease patients, infliximab was detected in serum for 12 weeks (range 4-28 weeks) after administration of the regimen.

Pediatrics

Infliximab pharmacokinetic characteristics (including peak and trough concentrations and terminal half-life) were generally similar in pediatric (aged 6 to 17 years) and adult patients with Crohn's Disease or Ulcerative Colitis following the administration of 5 mg/kg infliximab.

Population pharmacokinetic analysis based on data obtained from patients with ulcerative colitis (N=60), Crohn's disease (N=112), juvenile rheumatoid arthritis (N=117) and Kawasaki disease (N=16) with an overall age range from 2 months to 17 years indicated that the total clearance of infliximab did not increase linearly with increasing body weight. As a result, following administration of 5 mg/kg REMICADE® every 8 weeks, the predicted median steady-state infliximab exposure (area under concentration-time curve at steady state, AUC_{ss}) in pediatric patients aged 6 to 17 years was approximately 20% lower than the median steady-state drug exposure in adults. The median AUC_{ss} in pediatric patients aged 2 to less than 6 years was predicted to be approximately 40% lower than that in adults, although the number of patients supporting this estimate is limited.

NON-CLINICAL INFORMATION

Infliximab does not cross react with TNFα from species other than human and chimpanzees. Therefore, conventional preclinical safety data with infliximab are limited. In a developmental toxicity study conducted in mice using an analogous antibody that selectively inhibits the functional activity of mouse TNFα, there was no indication of maternal toxicity, embryotoxicity or teratogenicity. In a fertility and general reproductive function study, the number of pregnant mice was reduced following administration of the same analogous antibody. It is not known whether this finding was due to effects on the males and / or the females. In a 6-month repeated dose toxicity study in mice, using the same analogous antibody against mouse TNFα, crystalline deposits were observed on the lens capsule of some of the treated male mice. No specific ophthalmologic examinations have been performed in patients to investigate the relevance of this finding for humans.

Long-term studies have not been performed to evaluate the carcinogenic potential of infliximab. Studies in mice deficient in TNFα demonstrated no increase in tumours when challenged with known tumour initiators and/or promoters.

PHARMACEUTICAL INFORMATION

List of Excipients

Sucrose, polysorbate 80, monobasic sodium phosphate, dibasic sodium phosphate.

Incompatibilities

In the absence of incompatibility studies, this medicinal product must not be mixed with other medicinal products.

Shelf Life

Chemical and physical stability of the reconstituted solution has been demonstrated for 24 hours at room temperature (25°C). From a microbiological point of view, the product should be used

as soon as possible but within 3 hours of reconstitution and dilution. If not used immediately, in use storage times and conditions prior to use is the responsibility of the user and should not be longer than 24 hours at 2 to 8ºC.

See expiry date on the outer pack.

Storage Condition

Store at 2°C - 8°C.
REMICADE® may be stored at temperatures up to a maximum of 30ºC for a single period of up to 6 months; but not exceeding the original expiration date. The new expiration date should be written on the carton. Upon removal from refrigerated storage, REMICADE® cannot be returned to refrigerated storage.

Keep out of the reach and sight of children.

For storage conditions of the reconstituted medicinal product, see *Shelf Life*.

Nature and Contents of Container

REMICADE® is supplied as a lyophilised powder in single-use glass (Type 1) vials with rubber stoppers and aluminium crimps protected by plastic caps. REMICADE® is available in packs of 1, 2 or 3 vials. Not all pack sizes may be marketed.

Instructions for Use and Handling and Disposal

1. Calculate the dose and the number of REMICADE® vials needed. Each REMICADE® vial contains 100 mg infliximab. Calculate the total volume of reconstituted REMICADE® solution required.

2. Under aseptic conditions, reconstitute each REMICADE® vial with 10 ml of water for injections, using a syringe equipped with a 21-gauge (0.8 mm) or smaller needle. Remove flip-top from the vial and wipe the top with a 70% alcohol swab. Insert the syringe needle into the vial through the centre of the rubber stopper and direct the stream of water for injections to the glass wall of the vial. Gently swirls the solution by rotating the vial to dissolve the lyophilised powder. Avoid prolonged or vigorous agitation. DO NOT SHAKE. Foaming of the solution on reconstitution is not unusual. Allow the reconstituted solution to stand for 5 minutes. Check that the solution is colourless to light yellow and opalescent. The solution may develop a few fine translucent particles, as infliximab is a protein. Do not use if opaque particles, discolouration, or other foreign particles are present.

3. Dilute the total volume of the reconstituted REMICADE® solution dose to 250 ml with sodium chloride solution for infusion 9 mg/ml (0.9%). Do not dilute the reconstituted REMICADE® solution with any other diluent. This can be accomplished by withdrawing a volume of the sodium chloride solution for infusion 9 mg/ml (0.9%) from the 250-ml glass bottle or infusion bag equal to the volume of reconstituted REMICADE®. Slowly add the total volume of reconstituted REMICADE® solution to the 250-ml infusion bottle or bag. Gently mix. For volumes greater than 250 mL, either use a larger infusion bag (e.g. 500 mL, 1000 mL) or use multiple 250 mL infusion bags to ensure that the concentration of the infusion solution does not exceed 4 mg/mL.

4. Administer the infusion solution over a period of not less than the infusion time recommended (see *Dosage and Administration*). Use only an infusion set with an in-line, sterile, non-pyrogenic, low protein-binding filter (pore size 1.2 micrometer or less). Since

no preservative is present, it is recommended that the administration of the solution for infusion is to be started as soon as possible and within 3 hours of reconstitution and dilution. When reconstitution and dilution are performed under aseptic conditions, REMICADE® infusion solution can be used within 24 hours if stored at 2°C to 8°C. Do not store any unused portion of the infusion solution for reuse.

5. No physical biochemical compatibility studies have been conducted to evaluate the co-administration of REMICADE® with other agents. Do not infuse REMICADE® concomitantly in the same intravenous line with other agents.

6. Visually inspect REMICADE® for particulate matter or discolouration prior to administration. Do not use if visibly opaque particles, discolouration or foreign particulates are observed.

7. Discard any unused portion of the solution.

BATCH RELEASERS

Cilag AG
Hochstrasse 201, CH-8200
Schaffhausen, Switzerland

Janssen Biologics B.V.
Einsteinweg 101, 2333 CB Leiden
The Netherlands

PRODUCT REGISTRANT

Johnson & Johnson International (Singapore) Pte. Ltd.
2 Science Park Drive
#07-13, Ascent
Singapore Science Park 1
Singapore 118222

DATE OF REVISION OF THE TEXT

14 November 2022 (CCDS 20 December 2021)